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실험결과에 기뻐하며 때론 좌절에 빠져 내일을 기약하며 생활하다 
보니 어느덧 4 년 반이라는 세월이 지나 박사학위를 받게 되었습니다. 
학·연 과정 동안 서울로 기차를 타고 수업을 들으러 오가는 것이 힘들 
때도 있었지만, 한편으론 실험에 대한 생각과 삶에 대한 생각을 할 수 
있었기에 저에게는 소중한 시간이었습니다. 지난 세월을 되돌아 보며 
지금까지 도움을 주셨던 많은 분들에게 부족하나마 지면으로 그 고마움을 
전하고자 합니다.  
자주는 못 뵙지만 언제나 반갑게 맞아주시고 많은 가르침을 주신 
백융기 교수님, 옆에서 많은 조언과 실험실 생활에 많은 도움을 주신 
권병목 박사님, 프로젝트를 진행하면서 많은 고민을 해결해 주시고 
문제해결의 부족한 점을 채워주신 한동초 박사님께 감사의 마음을 전하고 
싶습니다. 그리고, 바쁘신 와중에 본 논문을 심사해주신 윤종복 교수님과 
김대원 교수님께 진심으로 감사 드립니다. 또한, 정겹게 웃어주시고 재치 
있는 말로 저희들을 즐겁게 해주시는 손광희 박사님과 같은 층에 계시는 
박호용 박사님, 김성욱 박사님 및 정태숙 박사님에게도 감사의 인사를 
전합니다.  
주말을 제외한 대부분의 시간을 같이 보내며 기쁨과 슬픔을 함께 나눌 
수 있었던 실험실 요원들이 있었기에 이 자리에 설수 있었던 것 같습니다. 
밤낮으로 열심히 실험하면서 실험실을 지키는 신대섭 박사, 자기 일에 
열심히 일하며 이제는 아기아빠가 된 종석씨, 한 가정의 가장이 된 
새신랑 지훈, 큰 웃음으로 연예계 소식을 전하는 진아, 날카로운 
눈빛으로 실험실을 이끄는 일꾼 소영, 일에 욕심 많은 혜난, 어려움이 
있어도 오뚝이처럼 잘 일어서는 영주, 뒷자리에 앉아서 엉뚱함으로 
웃음을 주는 영림, 묵묵하게 자기일에 열심인 영란, 밝게 웃으며 
백곰이라는 별명이 잘 어울리는 은진, 매사에 적극적인 사내대장부 같은 
란희, 그리고 항상 너털웃음 짓는 영민에게 고마움과 감사의 마음을 
전합니다. 
학위과정 동안 함께 일하며 도움을 준 많은 분들이 각자 자기의 일을 
찾아 떠났습니다. 실험실 생활하는 동안 많은 도움을 주신 김정민 
박사님과 강현미 박사님께 감사 드립니다. 처음 들어와 적응하는데 많은 
도움을 주었고 실험파트너였던 순복이, 큰 웃음이 매력인 미영이, 
짧았지만 많은 힘이 되었던 종환이와 성규에게도 진심으로 감사합니다. 
처음 학위 시작할 때 어색할 수 있는 학교실험실에서 마음 편히 쉴 수 
있게 공간을 마련해 주고 먼저 다가와 맞이해준 학교 실험실 식구들께 
고마운 마음을 전합니다. 낯선 환경에 잘 적응할 수 있도록 도움을 준 
지금은 미국계신 김기영 박사님과 신유경 박사, 실험에 열정적이었던 
정판영 박사님, 다정다감했던 조상연박사님, 언제나 편안하게 대해주시는 
이은영 박사님, 굿은 심부름과 어려운 부탁에도 열심히 도와준 효진, 
항상 웃으며 맞아 주었던 미정과 정의, 중국에서 낯선 한국으로 와서 
열심히 노력하는 영수씨와 허말, 그리고 이외에 실험실 식구들에게도 
모두 감사 드립니다.  
늦은 나이까지 공부하는 아들을 위해 많은 도움을 주시고, 멀리서 항상 
사랑으로 건강과 앞날을 기원해 주셨던 아버님, 어머님, 그리고 자식의 
일처럼 기뻐해 주셨던 장모님께 진심으로 감사의 인사를 올립니다. 항상 
곁에서 공부와 실험에 매진 할 수 있도록 내조를 잘해준 아내와 
존재만으로도 힘과 용기를 주는 딸 현송이와 아들 우진이에게 사랑한다는 
말을 전하고자 합니다. 
2008년 7월 
신기덕 올림 
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Characterization of a biphenyl isoxazole, KRIBB3, as an anti-migratory 
and anti-mitotic compound in Cancer Cell 
 
 
 
 
Ki Deok Shin 
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Cell migration is a prerequisite for cancer invasion and metastasis, 
suggesting cell motility as a potential therapeutic target for cancer treatment. A 
synthetic library was screened to identify inhibitors of tumor cell migration.  From 
this, I discovered CAC-1098 (aurintricarboxylic acid) and CBI-0997 (5-(2, 4-
dimethoxy-5-ethylphenyl)-4-(4-Bromophenyl) isoxazole) that inhibited migration of 
 xi 
MDA-MB-231 with an IC50 of 5 nM and 50 nM, respectively. I synthesized 
KRIBB3 (5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl) isoxazole) 
by replacing bromide group of CBI-0997 with methoxyl group. Like CBI-0997, 
KRIBB3 has anti-migratory and anti-invasive activity for MDA-MB-231. Because 
KRIBB3 has better drug-like structure, I focused my effort to understand its anti-
migratory mechanism further. Biotinyl-KRIBB3 was synthesized as an affinity 
probe for identification of KRIBB3-binding proteins. Using affinity chromatography, 
Hsp27 was identified as a target protein of KRIBB3 in vitro. Treatment of MDA-
MB-231 with PMA induced PKC-dependent phosphorylation of Hsp27 and tumor 
cell migration. In contrast, treatment of MDA-MB-231 with KRIBB3 blocked PMA-
induced phosphorylation of Hsp27 and tumor cell migration. Furthermore, 
overexpression of Hsp27 could antagonize inhibitory effect of KRIBB3 on tumor 
cell invasion and knockdown of Hsp27 using siRNA inhibited tumor cell migration. 
Overall, my results demonstrated that KRIBB3 inhibits tumor cell migration and 
invasion by blocking PKC-dependent phosphorylation of Hsp27 through its direct 
binding to Hsp27. 
During the test of anticancer effects by KRIBB3, I found that KRIBB3 
inhibited cell proliferation in several cancer cells. Especially, HCT-116 cells were 
inhibited cell growth with a GI50 of 0.35 µM. Flow cytometry study showed that 
KRIBB3 caused cell cycle arrest at G2/M phase and apoptosis. This was confirmed 
by detecting accumulation of Cyclin B1 and cleavage of poly (ADP-ribose) 
polymerase (PARP). While transient inhibition by KRIBB3 leaded to reversible 
mitotic arrest, prolonged exposure to the KRIBB3 induced apoptosis. Co-
 xii 
immunoprecipitation assay showed that KRIBB3 initially induced association of 
inhibitory Mad2 with p55CDC (mammalian homologue of CDC20), activator of 
APC/C (anaphase-promoting complex/cyclosome), suggesting that mitotic spindle 
checkpoint was activated by KRIBB3. However, this inhibitory complex of Mad2 
with p55CDC was gradually decreased 24 h after KRIBB3 treatment and was hardly 
detectable after 48 h, indicating slippage of mitotic checkpoint. Consistent with 
these observations, KRIBB3 activated the mitotic spindle checkpoint by disrupting 
microtubule cytoskeleton. KRIBB3 was proven to be a tubulin inhibitor using in 
vitro polymerization assays and in vivo indirect immunofluorescence staining. The 
temporal pattern of Bax activation by KRIBB3 was similar to PARP cleavage, 
suggesting that Bax is a mediator of KRIBB3-dependent apoptosis. Furthermore, 
when KRIBB3 was administered intraperitoneally into nude mice at 50 mg/kg or 
100 mg/kg, it inhibited 49.5% or 70.3% of tumor growth, respectively. These results 
suggest that KRIBB3 is a good drug candidate for cancer therapy. 
                                                                     
Keywords: migration, metastasis, Hsp27, chemical genetics, isoxazole, microtubule 
inhibitor, mitotic arrest, apoptosis, Bax activation, and cancer therapy  
 
 
 
 
 
 
 xiii 
Overview 
 
Metastasis is the most dangerous phenomenon causing decease of cancer 
patient. In metastasis, migration performs pivotal roles. The primary tumor cells 
move into blood vessels (intravasation) or the circulatory tumor cells invade into 
secondary organ tissue (extravasate). In addition, migration is participating in 
diseases processes, comprising vascular disease, osteoporosis, chronic inflammatory 
diseases, and mental retardation. More comprehensively understanding of cell 
migration mechanisms proffer us lots of advantage of therapeutic approaches for 
treating disease related with cell migration. 
 
Mechanism of Migration 
Cell migration cycles consist of sensing chemoattractant, cell polarity, 
protrusion, focal adhesion, and rear retraction. Moving cells have to sense gradient 
of chemoattractant, such as chemokines or growth factors. Cell membrane receptors 
such as G protein coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs) 
specifically recognize their chemokine ligands and growth factors. As a result, 
activated signaling pathways are remodeling of cytoskeleton and controlling cell 
migration. Recently, some ligands and receptors are reported to be involved in cell 
motility, such as CXCL12 (also known as SDF-1)/CXCR4, epidermal growth factor 
(EGF) or heregulin (HRG)/ErbB family, and hepatocyte growth factor (HGF)/Met 
(Kedrin et al., 2007).  
The polarized morphology is observed in the migrating cells. The microtubule 
 xiv
reorganization and arrangement of nucleus, microtubule organization center 
(MTOC), and Golgi are important to organize polarity, which is controlled by Cdc42. 
Unrevealed signaling pathway of linking integrins activate Cdc42. This affects the 
mPar6-atypical PKC (aPKC) complex, which inactivates GSK3 (Hall, 2005). The 
microtubule polarization and centrosome reorientation mechanism was not well 
understood, but recent evidence suggests that adenomatous polyposis coli (APC), 
CLIP170, IQGAP, and/or dynein/dynactin motor protein complex could be involved 
in microtubules local capture (Etienne-Manneville and Hall, 2003).  
After the complete of cell polarization, migration begins to produce the 
formation of protrusion in the moving direction. Activated GPCR and RTK 
stimulate phosphoinositide-3 kinase (PI3K) signaling pathway. The gradient sensing 
of chemoattractant brings about the localized accumulation of phosphoinosites 
(PIPs) on the leading edge, side, and rear. One of the PIP3 is produced at leading 
edge that is activated by PI3K. PIP3 activates guanine-nucleotide exchange factors 
(GEFs) that control the Rho GTPases activity, such as Rac, Cdc42, and Rho 
(Charest and Firtel, 2007; Kedrin et al., 2007; Pullikuth and Catling, 2007). 
However, RhoA/ROCK signaling pathway phosphorylates PTEN known as PIP3 
phosphatase that covert PIP3 into PIP2. The phospho-PTEN moves to the side and 
rear so that PIP2 exists there and blocks the protrusion. The reason of protrusion 
occurred in leading edge is because of PTEN and Myosin II. The Arp2/3 (actin 
related protein 2/3) complex induces actin polymerization, which binds to the 
Wiscott-Aldrich Syndrome (WASP) and WAVE (WASP family verprolin 
homology) through a VCA region (verprolin homology domain, cofilin homology 
 xv 
domain, and acidic region). The local activation of Rac controls WAVE protein that 
leads to lamellipodia formation. WASP, the downstream target of Cdc42, regulates 
filopodia formation in the direction of migration (Sasaki and Firtel, 2006). Unlike 
Arp2/3 complex, formins are another actin polymerization factors that relate with 
ruffle dynamic at the leading edge of moving cell. The formin-nucleated filament 
elongation is regulated by profilin, which is associated with the FH1 domain of 
formin. ADF/cofilin severs and depolymerizes ADP-filament, which is converted 
for ATP-actin by profilin (Chhabra and Higgs, 2007). 
Cell movement toward leading edge requires new focal adhesion that is 
mediated by integrins; these heterodimeric transmembrane receptor consisting with 
α and β subunit, contact with ECM ligands. Clustered integrins bind α-actinin, talin, 
focal adhesion kinase (FAK), and tensin. These proteins interact with actin-binding 
proteins, such as vinculin and paxillin. Vinculin provides a connection between the 
actin/Arp2/3 complex and emerging focal contacts. FAK controls the cycle of 
assembly and disassembly of focal adhesion; FAK-PI3K signaling activates Rac 
through Rac GEF and FAK-p130Cas-Crk-DOCK180 complex also activate Rac. 
Furthermore, Rac activation is required for down-regulation of Rho by FAK-Src 
phosphorylation of p190RhoGAP and FAK binding p190RhoGEF (Moissoglu and 
Schwartz, 2006).  
The cell motility cycle is completely done by rear retraction. The rear 
retraction consists of actin contraction and focal contact disassembly. Cell 
contraction is induced by actin filament (actomyosin) which is activated by Myosin 
II. Myosin II is activated by Ca2+- and calmodulin-dependent myosin light-chain 
 xvi
kinase (MLCK) pathway or deactivated by dephosphorylation via the MLC 
phosphatase (MLCPtase) which is regulated by Rho-associated serine/threonine 
kinase (ROCK) via Rho GTPase pathway (Clark et al., 2007). In focal contact 
disassembly, calpain protease and calcineurin phosphatase are important calcium 
activated target protein that cleave focal contact proteins. In addition, FAK activates 
ERK2, which promotes Calpain-2-mediated cleavage of focal-adhesion proteins 
(Carragher et al., 2003; Franco et al., 2004). After rear adhesion disassemble is 
completed, main cell body is slowly glide forward. (Fig.1.). All the proteins 
discussed above can be target molecules of searching migration inhibitors. 
 
Migration inhibitors 
Migrastatin is a macrolide natural product first isolated from a culture broth of 
a Streptomyces. Migrastatin inhibits several types of tumor cell migration (IC50 =29 
µM) in vitro, but has no effect on the biosyntheses of DNA, RNA, and protein in 
theses cells (Nakae et al., 2000). Recently, more potent synthetic analogs of 
migrastatin have been reported to inhibit tumor cell migration with sub-micromolar 
IC50 values (Metaferia et al., 2007; Njardarson et al., 2004; Shan et al., 2005). 
Migrastatin inhibits lamellipodium formation at the leading edge of cells by 
inhibiting Rac activation. 
Rockout is a 3-4(-pyridyl)indole compound that inhibits cell migration 
(Yarrow et al., 2005). Yarrow and his colleagues performed a visual screening based 
on classical wound healing assays in a high-throughput format. They screened 
inhibitors from library of 16,000 chemicals and identified a new Rho-kinase 
 xvii
inhibitor. Rho-kinase is important target of small molecule because it contributes to 
control actin contraction and rear retraction. 
Locostatin (UIC-1005) is an oxazolidinone derivative compound that inhibits 
cell locomotion in multiple systems (Zhu et al., 2005). The biological activity of 
locostatin was discovered by an epithelial wound closure assay system (Mc Henry et 
al., 2002). The target of locostatin is Raf kinase inhibitor protein (RKIP). It disrupts 
a protein-protein interaction between RKIP and Raf-1 kinase. RKIP plays a critical 
role in epithelial cell migration (Zhu et al., 2005). 
DX-52-1 is an analog of quinocarmycin. It was discovered from wound-
healing assay with epithelial cell. By using pulldown assay, radixin was identified as 
a relevant molecular target of DX-52-1 (Kahsai et al., 2006). Radixin is one of the 
members of ezrin/radixin/moesin (ERM) protein family, which functions as 
membrane-cytoskeleton linkers. Radixin, membrane-associated and actin-binding 
protein, is important for organization of the membrane-associated cortical actin 
cytoskeleton, cell migration, adhesion, and proliferation (Hoeflich and Ikura, 2004). 
Furan-2-ylmethylene thiazolidinediones (AS-252424) is a specific ATP-
competitive PI3Kγ (p110γ) inhibitor (Pomel et al., 2006). PI3Kγ inhibitors were 
achieved using a proprietary substructure analysis method. Thus, a set of selected 
59,000 compounds was tested with PI3Kγ enzyme inhibition assay. The PI3K 
pathway promotes proliferation and survival in many different cell types. Therefore, 
PI3Kγ knockout (KO) mice revealed reduced neutrophil migration to infection sites 
induced by chemoattractant and respiratory burst (Condliffe et al., 2005; Hirsch et 
al., 2000; Li et al., 2000; Sasaki et al., 2000). PI3Kγ is thought to be important role 
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in mediating leukocyte chemotaxis as well as mast cell degranulation. Thus, PI3Kγ 
may be an attractive target for autoimmune and inflammatory diseases (Camps et al., 
2005; Wymann et al., 2003). 
Two classes of small molecular suppressor have been developed using a target 
of Integrin αLβ2 (lymphocyte function associated antigen-1 (LFA-1)) which is 
related with inflammatory diseases. One group of antagonist is LFA703 and 
BIRT377, which bind the hydrophobic pocket underneath the Integrin α7 helix of 
the αL I domain (Weitz-Schmidt et al., 2001; Wu et al., 2004). These antagonists are 
called as an α
 
I allosteric inhibitors (Yang et al., 2006). The other group of 
antagonists bind to the metal ion-dependent adhesion site (MIDAS) of the β2 I-like 
domain, as well as to a region of the αL subunit that does not include the I domain 
(Shimaoka et al., 2003; Welzenbach et al., 2002). This antagonist, such as XVA143, 
is called as an α/β I-like allosteric inhibitor (Salas et al., 2004; Yang et al., 2006). 
Controlling of αLβ2 activation is critical for regulating leukocyte movement and 
immune reactions. Thus, αLβ2 is a good target for treating autoimmune and 
inflammatory diseases (Gottlieb and Bos, 2002; Yusuf-Makagiansar et al., 2002). 
Recently, Slack-Davis and colleagues discovered inhibitor of FAK, PF-228 
(Slack-Davis et al., 2007). PF-228, (6-[(4-((3-(methanesulfonyl)benzyl)amino)-5-
trifluoromethylpyrimidin-2-yl)amino]-3,4-dihydro-1H-quinolin-2-one) is a 
competitive inhibitor of ATP with specificity for FAK family protein-tyrosine 
kinases. This inhibitor was screened using commercially available recombinant 
enzymes. Several studies show that FAK expression and/or activity is related with 
cell growth and migration by adhesion dependent signaling pathway. Interestingly, 
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PF-228 specifically regulates cell migration, but it does not inhibit cell growth nor 
induce apoptosis in vitro. Thus, PF-228 provides an useful tool to in-depth study of 
FAK related signaling in cell adhesion dynamic. 
 
Perspective 
Migration inhibitors discussed above have been identified using enzyme-
based assay or phenotype-based assay. In decades, many researchers have been 
studying the cell migration in different cells and diseases. Therefore, they disclosed 
important molecules and signaling pathways in cell motility procedures, such as 
chemoattractant sensing, cell polarity formation, protrusion, integrin, adhesion 
formation, and retraction, which become attractive therapeutic targets in drug 
discovery. However, unrevealed mechanisms of cell migration are remaining in 
these fields. In recent years, Yarrow and his colleagues developed a cell image-based 
screening system by wound healing assay. This kind of phenotypic screening 
method has been useful tools for screening of small molecules, siRNA, and protein 
libraries. Additionally, phenotypic screening method may be provided with solution 
of many unrevealed proteins or diverse migration-related pathways in cell migration. 
In spite of many endeavors to understanding of cell migration, our in vitro studying 
tools are not a mimic the microenvironment. Therefore, we do not exactly 
understand a mechanism of cell migration in vivo. In the future, we have to 
overcome these issues and effort to discover the tools of mimic the 
microenvironment and develop the equipment of detecting or monitoring the single 
cell movement in that microenvironment. 
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Fig. 1. Key regulatory molecules of cell migration  
(modified fromRidley et al., 2003). 
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Table 1. Structure of inhibitor of cell migration. 
Name Structure Screen Method/Mode of Action 
Migrastatin 
 
Inhibit Rac activation 
Rockout 
 
Wound healing assay/Rho kinase 
inhibitor 
Locostatin 
(UIC-1005) 
 
Wound closure assay/RKIP 
DX-52-1 
 
Wound healing assay/Radixin 
AS-252424 
 
Enzyme based assay/PI3Kγ inhibitor 
LFA703 
 
lovastatin-based series of designed 
compounds/LFA-1 (α
 
I allosteric) 
inhibitor 
BIRT377 
 
LFA-1/ICAM-1 binding assay/LFA-1 (α
 
I allosteric) inhibitor 
XVA143 
 
LFA-1-ICAM-1 ELISA-type binding 
assay/LFA-1 (α/β I-like allosteric) 
inhibitor 
PF-228 
 
Enzyme based assay/FAK inhibitor 
KRIBB3 
 
Boyden chamber assay/Hsp27 inhibitor 
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Part Ⅰ. 
 
Blocking tumor cell migration and invasion with biphenyl isoxazole 
derivative KRIBB3, a synthetic molecule that inhibits Hsp27 
phosphorylation 
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Abstract 
 
Cell migration is a prerequisite for cancer invasion and metastasis, 
suggesting cell motility as a potential therapeutic target for cancer treatment. A 
synthetic library was screened to identify inhibitors of tumor cell migration.  From 
this, I discovered CAC-1098 (aurintricarboxylic acid) and CBI-0997 (5-(2, 4-
dimethoxy-5-ethylphenyl)-4-(4-Bromophenyl) isoxazole) that inhibited migration of 
MDA-MB-231 with an IC50 of 5 nM and 50 nM, respectively. I synthesized 
KRIBB3 (5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl) isoxazole) 
by replacing bromide group of CBI-0997 with methoxyl group. Like CBI-0997, 
KRIBB3 has anti-migratory and anti-invasive activity for MDA-MB-231. Because 
KRIBB3 has better drug-like structure, I focused my effort to understand its anti-
migratory mechanism further. Biotinyl-KRIBB3 was synthesized as an affinity 
probe for identification of KRIBB3-binding proteins. Using affinity chromatography, 
Hsp27 was identified as a target protein of KRIBB3 in vitro. Treatment of MDA-
MB-231 with PMA induced PKC-dependent phosphorylation of Hsp27 and tumor 
cell migration. In contrast, treatment of MDA-MB-231 with KRIBB3 blocked PMA-
induced phosphorylation of Hsp27 and tumor cell migration. Furthermore, 
overexpression of Hsp27 could antagonize inhibitory effect of KRIBB3 on tumor 
cell invasion and knockdown of Hsp27 using siRNA inhibited tumor cell migration. 
Overall, my results demonstrated that KRIBB3 inhibits tumor cell migration and 
invasion by blocking PKC-dependent phosphorylation of Hsp27 through its direct 
binding to Hsp27. 
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1. Introduction 
 
Traditionally, genetic mutagenesis has proven to be a useful tool in solving 
the function of wide range of genes in biological process. Recently, chemical genetic 
approach has been developed to elucidate the principles of a wide range of 
biological processes (for review, (Mayer, 2003; Schreiber, 1998; Stockwell, 2004)). 
Metastasis plays a major role in morbidity and mortality from breast cancer 
(Mundy, 2002). Potential of metastasis of cancer cell is related with ability to digest 
the extracellular matrix, migrate, cross blood vessel walls, and reach the blood 
circulation (for review, (Chambers et al., 2002; Friedl and Wolf, 2003; Hood and 
Cheresh, 2002; Pantel and Brakenhoff, 2004)). Cell movement is a complex process 
involving a number of steps, including the disruption of cell-cell junctions, 
cytoskeletal rearrangements, and the constant remodeling of adhesive contacts with 
the extracellular matrix (for review, (Franz et al., 2002; Lauffenburger and Horwitz, 
1996; Ridley et al., 2003)). Cell migration contributes to several other important 
pathological processes, including vascular disease, osteoporosis, chronic 
inflammatory disease such as rheumatoid arthritis and multiple sclerosis, cancer, and 
mental retardation. 
Anticancer drug development strategy has traditionally focused on inhibitor 
of cancer cell growth. However, other processes in the tumor progression can be 
potential targets for cancer treatment. Among these, migration is one of interesting 
processes for tumor progression. Expression of different growth factor receptors in 
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malignant cells was reported and could participate not only in transducing growth 
signals but also contribute to the motile properties of malignant cancer cell. Multiple 
growth factors and their receptors are involved in the malignant progression (van der 
Valk et al., 1997). The number of cells expressing multiple growth factors and their 
receptors tends to increase with increasing malignancy grade. High metastatic cells 
exhibit higher spontaneous rate of migration as compared with their low-metastatic 
counterparts (Clark et al., 2000; Volk et al., 1984). 
 Hsp27 (heat shock protein of 27 kDa) belongs to a family of abundant and 
ubiquitous stress proteins which are detectable in virtually all organisms from 
prokaryotes to mammals (Concannon et al., 2003). In unstressed cells, Hsp27 levels 
are generally low, and it exists predominantly as a large oligomeric unit of up to 800 
kDa.  The size of this oligomeric unit is dependent on a number of parameters, 
including temperature and degree of phosphorylation of Hsp27 (Lavoie et al., 1995; 
Zantema et al., 1992). During the stress condition, an increase in the level of Hsp27 
expression is preceded by a phosphorylation-induced reorganization of the 
multimeric status of the Hsp27. Phosphorylation occurs on four different residues, 
Ser-15, Ser-78, Ser-82, and Thr-143 and this induces redistribution of the large 
oligomers to small tetrameric units (Lavoie et al., 1995; Zantema et al., 1992). 
Phosphorylation of Hsp27 catalyzed by MAKPAP kinase 2 and 3 (Landry et al., 
1992; Ludwig et al., 1996; Stokoe et al., 1992), PKC (Maizels et al., 1998), cGMP-
dependent protein kinase (Butt et al., 2001), and PKD (Doppler et al., 2005). The 
increased phosphorylation of Hsp27 is detectable several minutes after exposure to 
stress and subsequent increase in the expression level of the protein is detectable 
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within several hours (Landry et al., 1991). Hsp27 has been recognized as a potent 
regulator of cytoskeleton dynamics, actin microfilaments. Actin cytoskeleton is 
modulated by both the spatial arrangement as well as the polymerization dynamics 
of its different elements (Liang and MacRae, 1997). Overexpression of Hsp27 
increases the stability of F-actin microfilaments during exposure to stress (Guay et 
al., 1997; Huot et al., 1995; Lavoie et al., 1993). The exact mechanism by which 
Hsp27 stabilizes F-actin is poorly characterized. Actin microfilaments are not the 
only components of the cytoskeleton that have been reported to interact with Hsp27. 
Hsp27 colocalizes with tubulin/microtubles (Hino et al., 2000). Higher levels of 
Hsp27 expression are commonly detected in variety different cancers including 
breast (Love and King, 1994; Oesterreich et al., 1993), prostate (Cornford et al., 
2000), gastric (Chen et al., 2004; Ehrenfried et al., 1995), and ovarian (Langdon et 
al., 1995) cancer.  Several studies point to the ability of Hsp27 to increase the 
metastatic potential of tumor cells in nude mice as well as enhancing their resistance 
to therapy (Blackburn et al., 1997; Katoh et al., 2000).  
 I now report that I have identified anti-migratory compounds by chemical 
library screening. One of inhibitors, KRIBB3, inhibited both tumor cell migration 
and invasion. In addition, I found that KRIBB3 bound to Hsp27 and inhibited cell 
migration by blocking PKC-dependent Hsp27 phosphorylation. 
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2. Materials and Methods 
 
2.1. Materials 
 
Monoclonal anti-phospho-Hsp27 (ser 78) antibody was purchased from 
Upstate Biotechnology. Antibodies against Hsp27, AKT, phospho-AKT, phospho-
PKCµ(mu), and phospho-PLCβ3 were purchased from Cell Signaling. Antibodies 
against FAK, p130Cas, and PY-20 were purchased from transduction laboratories 
(Lexington, KY). Chemicals used in these experiments were purchased from Sigma 
Chemical (St. Louis, MO) and Calbiochem (San Diego, CA). CAC-1098 
(aurintricarboxylic acid) was purchased from Sigma Chemicals (St. Louis, MO) and 
CBI-1098 (5-(2, 4-dimethoxy-5-ethylphenyl)-4-(4-Bromophenyl) isoxazole) and 
KRIBB3 (5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl) isoxazole) 
were synthesized in my laboratory.  
 
2.2. Cell culture 
 
The cell lines used were obtained originally from ATCC. MDA-MB-231 
(human breast cancer cell line) was maintained in RPMI 1640 (Gibco/BRL) 
supplement with 10% heat inactivated FBS (Gibco/BRL) and 25 mM Hepes. Cell 
cultures were maintained at 37  under a humidified atmosphere of 5% CO℃ 2 in an 
incubator. 
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2.3. Construction of Hsp27 overexpressing MDA-MB-231 cell line 
 
Full length Hsp27 was obtained by PCR using sense (5’-
CGCGGATCCATGACCGAGCGCCGCGTCC-3’) and antisense (5’-
GGAATTCGTGGGCATCCGGGCTAAGG-3’) oligonucleotides with an expressed 
sequence tag clone containing Hsp27 (Korea UniGene Clone ID hMU001508, 
cDNA clone MGC: 21487) as a template. The PCR product was digested with 
BamHI and EcoRI, and then inserted into a mammalian expression vector 
pcDNA3.1 that had been digested with BamHI and EcoRI. To generate cells stably 
expressing Hsp27, MDA-MB-231 cells were transfected using Lipofectamine and 1 
µg of pcDNA3.1-Hsp27. Clones were selected in growth medium containing 0.8 
mg/ml G418 for 21 days. In order to avoid colony-specific variation, I used whole 
population of selected colonies for further study. 
 
2.4. Knockdown of Hsp27 protein by using Hsp27 siRNA 
 
The Hsp27 siRNA and control siRNA were purchased from Cell Signaling 
(Beverly, MA). Cells plated at a density of 8104 cells per well in six-well plates 
were transfected with 100 nM of Hsp27 specific and control small interfering RNA 
(siRNA) oligoduplexes after a preincubation for 20 min with oligofectamine in 
serum free OPTI-MEM (Invitrogen-Life Technologies, Inc.). Four hours after the 
beginning of the incubation, the medium was added with the RPMI 1640 containing 
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3X the normal concentration of serum (without antibiotics). 48 hours after 
transfection, cells were collected and used for migration assay or for preparation of 
whole cell lysates. 
 
2.5. Cell proliferation assays 
 
Proliferation assay was done, as described previously (Han et al., 2004). 
Briefly, cells (5,000 cells) were seeded into 96 well plates in RPMI 1640 containing 
10% FBS. After 20-24 h, cells were replenished with fresh complete medium 
containing either a test compound or 0.1% DMSO. After incubation for 48 h, cell 
proliferation reagent WST-1 (Roche Applied Science) was added to each well. The 
amount of WST-1 formazan produced was measured at 450 nm using an ELISA 
Reader (Bio-Rad, CA). 
 
2.6. Cell migration assays 
 
Migration was measured using a 48-well Boyden chamber (Neuroprobe 
Inc., Gaithersburg, MD). Various concentrations of chemicals in RPMI 1640 
medium with 10% FBS were placed into the base wells separated from the top wells 
by polycarbonate filters (Neuroprobe Inc., 8 µm pore size, 2580 mm, PVP-free). 
Cells were harvested by trypsinization, washed once with serum-free RPMI 1640 
medium containing 0.5 mg/ml soybean trypsin inhibitor (Sigma, St Louis, MO), and 
then washed twice with serum-free RPMI 1640 medium. Cells were resuspended in 
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serum-free RPMI 1640 medium and added to the upper chamber at 8103 cells per 
well. Cells were incubated for 16 h at 37℃ in 5% CO2 humidified incubator. At the 
end of experiment, cells were fixed with methanol for 10 min and stained with 
modified Giemsa stain (Sigma, St Louis, MO) for 1 hr. Cells on the upper side of the 
membrane were then removed by cotton swab. The migrated cells were counted 
under light microscope at 100  magnifications. 
Several known inhibitors of kinase were used at concentration indicated; 
Rottlerin (PKC-δ inhibitor, 5 µM):, PD98059 (MEK inhibitor, 40 µM):, 
Bisindolylmaleimide I (broad PKC inhibitor, 5 µM):, Y-27632 (ROCK inhibitor, 10 
µM):, Wortmanin (PI3 kinase inhibitor, 10 µM):, SB203580 (p38 MAPK inhibitor, 
10 µM):, AG1478 (EGFR inhibitor, 10 uM):, and PP2 (Src inhibitor, 50 uM). 
 
2.7. Cell invasion assay 
 
MDA-MB-231 cells were starved for overnight in serum-free RPMI 1640 
medium. Thawed Matrigel (BD Bioscience, MA) was diluted 1:20 with 1  RPMI 
and 100 µl was used to coat each invasion chamber (Transwell, BD Bioscience, 
MA) equipped with an 8 µm pore size micropore filter. After the chambers were 
incubated at 37℃ for 1 hr, unbound matrigel was aspirated and rinsed gently using 
serum-free RPMI 1640 medium. Matrigel barrier was reconstituted with 100 µl 
serum-free medium for 2 h at 37℃. In the meantime, MDA-MB-231 cells were 
harvested after trypsinization, washed once with serum-free RPMI 1640 medium 
containing 0.5 mg/ml soybean trypsin inhibitor (Sigma, St Louis, MO), and then 
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washed twice with serum-free RPMI 1640 medium. Cells were diluted to 1105 
cells/ml and 200 µl was inoculated into upper chamber. 10% FBS as 
chemoattractant was added to the 24 well culture dishes. After incubation at 37℃ 
for 24 h, the Matrigel on the filter was removed with a cotton swab. The filter was 
then stained with crystal violet (300 ㎕ of 5 mg/ml crystal violet dissolved in 20% 
Methanol) and incubated for 30 min. The membrane was washed several times with 
1PBS and the cells that had penetrated the filter were counted under a microscope. 
 
2.8. Western Blotting and immunoprecipitation 
 
Lysates were prepared using RIPA buffer, as described previously (Han et 
al., 2004). A 40 µg protein was resolved by 7.5% or 10% SDS-PAGE and 
transferred to PVDF membrane (Roche, Germany). Membrane was blocked with 1% 
Western Blocking Reagent (Roche, Germany) in TBS-T (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 0.05% Tween 20). The primary antibodies were used as 
recommended by the manufactures. The secondary antibodies used were horseradish 
peroxidase-conjugated goat anti-rabbit or anti-mouse IgG (Jackson 
ImmunoResearch Laboratories, Inc.). The membrane was incubated with primary 
antibody for 2 h at room temperature, washed 3 times with TBS-T, and visualized 
with chemiluminescent β-peroxidase reagents (Roche, Germany). For 
immunoprecipitation, 400 µg of lysates were incubated with primary antibody for 2 
h at 4℃ in rotary shaker and then, 40 µl of protein G-agarose beads were added. 
After 1 hr, beads containing lysates were centrifuged and washed 3 times with lysis 
 12 
buffer. Beads-bound proteins were resolved by SDS-PAGE and immunoblotted 
using specific antibody. 
 
2.9. Detection of KRIBB3-binding proteins 
 
MDA-MB-231 cells were washed with PBS and then homogenized with a 
27G syringe in binding buffer (10 mM Tris-HCl pH 7.4, 50 mM KCl, 5 mM MgCl2, 
1 mM EDTA, and 0.1 mM Na3VO4). The cell lysate was centrifuged at 13,000 rpm 
for 30 min at 4℃, and the supernatant was collected. After the supernatant of MDA-
MB-231 cells had been precleared by incubating with immobilized streptavidin 
(Sigma Chemical Co., St. Louis, MO) for 60 min at 4℃ followed by centrifugation 
at 500  g for 5 min, the cleared supernatants were incubated with biotinyl-
KRIBB3 compound. After incubation for 2 h at 4℃, proteins associated with the 
biotinyl-KRIBB3 compound were precipitated with UltraLink-Immobilized 
NeutrAvidin-agarose (PIERCE Biotechnology, Rockford, IL). Precipitated samples 
were applied to the column. Samples were washed with 10 bed volumes of washing 
buffer containing 50 mM HEPES pH 7.5, 30 mM NaCl, 1 mM EDTA, 2.5 mM 
EGTA, 0.1% Tween 20, 10% (v/v) glycerol, 1 mM NaF, 0.1 mM Na3VO4, and 
Protease Inhibitor Cocktail Tablets (1 tablets/10 ml; Roche, Germany). Samples 
were eluted from the column with 5 bed volumes of the elution buffer (0.1 M 
glycine•HCl pH 2.8). Samples were boiled in SDS-PAGE sample buffer, separated 
by 10% polyacrylamide gel, and visualized by Coomassie Briliant Blue stainging. 
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2.10. Peptide analysis of the KRIBB3-binding protein  
 
Specific KRIBB3-binding protein in gel was cut out and sent to Korea Basic 
Science Institute (Daejeon, Korea) for peptide analysis. Sample was digested with 
trypsin. Peptide tandem mass spectrometry analysis of the digested peptides was 
performed using an electrospray ionization quadrupole time-of-flight mass 
spectrometer as described previously (Nam et al., 2003). 
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3. Results 
 
3.1. Screening of anti-migratory chemicals 
 
 I sought anti-migratory compounds by using cell-based screening. Whole 
cell based assay was preferred because of its ability to simultaneously assess 
multiple targets. In addition, this approach can avoid problems with drug 
permeability by identifying active compounds that freely enter the cell. The effect of 
chemicals on the cell migration of MDA-MB-231 cells was measured by using 
modified Boyden Chamber assay (Fig. 2). Cell migration was performed in the 
presence of 10 µM of chemical and 10% FBS was used as a chemoattractant.  The 
components provided by serum are certain highly specific proteins called growth 
factors. Serum containing growth factors are IGF-1 (insulin-like growth factor 1), 
EGF (epidermal growth factor), and PDGF (platelet-derived growth factor). 
In screening ∼12,000 synthetic chemicals for compounds, “cell stoppers”, 
that inhibit migration of human breast cancer cell line MDA-MB-231, I identified 
CAC-1098 (aurintricarboxylic acid) and CBI-0997 (5-(2, 4-dimethoxy-5-
ethylphenyl)-4-(4-Bromophenyl) isoxazole) (Fig. 3).  The CAC-1098 and CBI-
0997 inhibited migration of MDA-MB-231 with an IC50 of 5 nM and 50 nM, 
respectively (Fig. 4A). 
To clarify whether the inhibitory action on motile functions could be due to 
a cytotoxic effect, the cell stoppers were tested for its effect on MDA-MB-231 cell 
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proliferation. The cell stopper, CAC-1098 and CBI-0997 inhibited proliferation of 
MDA-MB-231 with a GI50 of > 100 µM and 25 µM, respectively (Fig. 4B). These 
results indicate that the cell stoppers significantly inhibit cell migration at 0.1-1 µM 
without cytotoxic problem. 
I synthesized several CBI-0997 derivatives and analyzed their anti-
migratory activities (unpublished data). From this study, I found that replacement of 
bromide with methoxyl group did not change its anti-migratory activity and I 
decided to study methoxyl derivative further.  I called methoxyl derivative, (5-(5-
ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl) isoxazole) as “KRIBB3” 
(Fig. 3). KRIBB2 (4-ethyl-5-methoxy-2(3-methyl-4-phenylisoxazole-5-yl) phenol) 
was an inactive analogue of KRIBB3 and used as a negative control. 
CAC-1098 (aurintricarboxylic acid; ATA), another identified cell stopper, 
is a polymeric carboxylated triphenylmethane derivative (Fig. 3). Aurintricarboxylic 
acid was reported as an angiogenesis inhibitor (Gagliardi and Collins, 1993). It has 
been reported to have antiproliferative activity to vascular smooth muscle cells 
(Benezra et al., 1994). However, when MDA-MB-231 cells were treated with ATA, 
more than 80% of cell migration was inhibited by 0.01 µM of ATA. In addition, I 
could not detect any antiproliferative activity of ATA up to 10 µM (Fig. 4A and B). 
This result implies the possibility that ATA may inhibit angiogenesis by inhibiting 
migration of vascular endothelial cells.  It will be interesting to test this possibility. 
Successful identification of previously known anti-angiogenesis compound 
validated my approach to identify novel compound that may inhibit cell migration. 
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3.2. Inhibition of tumor invasion by cell stopper 
 
Invasive behavior of cancer cell is accompanied with increased cell 
movement. This suggests that cell stopper can block invasion of tumor. The effect of 
cell stoppers on the MDA-MB-231 cells to invade through Matrigel-coated porous 
filters in response to a chemotactic stimulus was examined in an 8 µm pore size 
invasion chamber assay. Cells were treated with cell stoppers at different 
concentration (0-100 µM) for 24 h, and I used 10% FBS as a chemoattractant. CAC-
1098 and KRIBB3 inhibited invasion of MDA-MB-231 cell in a dose dependent 
manner, with half maximal inhibition at 2.8 µM and 0.15 µM, respectively (Fig. 5A 
and B). Especially, invasion was almost completely blocked by 1 µM concentration 
of KRIBB3 (by ∼90%). 
 
3.3 Analysis of phosphorylation of FAK, p130Cas, and AKT 
 
When cells were treated with KRIBB3, they became round in morphology 
within 5 min (Fig. 6A). Cells treated with vehicle, DMSO, did not induce any 
detectable morphological changes (data not shown). Spreading of cell is regulated 
by integrin receptors and its ligands, ECM. Activation of integrins induces 
phosphorylation of many focal adhesion proteins, including FAK (Guan and 
Shalloway, 1992) and p130Cas (Vuori and Ruoslahti, 1995). Cells lacking the 
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tyrosine kinase FAK or Src have more and larger adhesions and migrate poorly 
(Alahari et al., 2002; Webb et al., 2002). The interaction of FAK with Src and the 
adaptor proteins p130Cas and Crk appears to regulate adhesion turnover. Therefore, I 
analyzed tyrosine phosphorylation of whole cell lysates or specific focal adhesion 
proteins after immunoprecipitation. In general, tyrosine phosphorylation of whole 
cell lysate increased after KRIBB3 treatment and reached maximum 3 h after the 
treatment and then, gradually decreased (Fig. 6B). However, profile of tyrosine 
phosphorylation of whole cell lysate was not altered by treatment with DMSO. In 
order to test whether FAK was tyrosine phosphorylated by KRIBB3, FAK was 
immunoprecipitated with anti-FAK antibody and blotted with phosphotyrosine-
specific antibody. As shown in Fig. 7A, I could not detect any decrease of FAK 
phosphorylation. In contrast, I could see significant increase of FAK 
phosphorylation 3 h after KRIBB3 treatment. Similarly, p130Cas was 
immunoprecipitated with anti-p130Cas antibody and analyzed with phosphotyrosine-
specific antibody. However, I could not detect any decrease of p130Cas 
phosphorylation (Fig. 7B). These suggest that FAK or p130Cas are not involved in 
KRIBB3-induced anti-migratory activity.  
Directed cell migration toward a soluble growth factor is a general 
phenotype of motile cells and requires highly polarized intracellular signaling events 
promoting the recruiting of the PH-domain containing proteins to the leading edge 
(Firtel and Chung, 2000; Parent and Devreotes, 1999). This localized increase of 
phosphatidylinositol-3-phosphates is the result of spatial activation of PI-3-kinase 
(Funamoto et al., 2002). Therefore, I examined PI-3-kinase activity by measuring 
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amount of phosphorylated AKT, effector of PI-3-kinase. In this case, I found small 
increase of AKT phosphorylation 1 hr after KRIBB3 treatment and I could not see 
any inhibition of PI-3-kinase activity (Fig. 7C). This result suggested that KRIBB3 
did inhibit cell migration not via PI-3-kinase, neither. When cells were treated with 
DMSO, phosphorylation of FAK, p130Cas, or AKT was not changed (data not 
shown). 
 
3.4. Target identification of KRIBB3 
 
 Target identification represents a major challenge for all forward-chemical 
genetic screening. Biochemical purification has been the method of choice for target 
identification. The generally used method is to immobilize the compound via a 
chemical linker on a solid phase support, followed by affinity purification of the 
cellular target. Therefore, I synthesized biotin-linked KRIBB3. For this, hydroxyl 
group of KRIBB3 was covalently attached to butyl-biotin moiety. The synthesized 
biotinyl-KRIBB3 has acceptable anti-migratory activity (IC50 is 0.2 µM). KRIBB2 is 
a KRIBB3 analogue lacking biological activity and biotinyl-KRIBB2 was 
synthesized for negative control. 
 Cell extracts of MDA-MB-231 cells were incubated with biotinyl-KRIBB3 
or biotinyl-KRIBB2 or biotin. The bound proteins were precipitated with 
NeutrAvidin beads and bound proteins were detected by using Coomassie Brilliant 
Blue staining. A 30 kDa protein was detected as a biotinyl-KRIBB3 binding protein. 
This band was analyzed by ESI-Q-TOF mass spectrometer in Korea Basic Science 
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Institute and was identified as an Hsp27 protein (Fig. 8A and B). I wanted to 
confirm the 30-kDa protein as an Hsp27 by using Hsp27-specific antibody. The 
proteins bound to biotin- NeutrAvidin, biotinyl-KRIBB2- NeutrAvidin beads, or 
biotinyl-KRIBB3- NeutrAvidin beads were resolved using SDS-PAGE and 
separated bands were transferred onto a membrane. Then, Hsp27 band was 
visualized by using an anti-Hsp27 antibody. As shown in Fig. 8C, the Hsp27 band 
was only detected from biotinyl-KRIBB3 lane.  In addition, when interaction 
between Hsp27 and biotinyl-KRIBB3 was challenged by excess of KRIBB3, the 
interaction between Hsp27 and biotinyl-KRIBB3 was decreased (Fig. 8D).  These 
results support strongly that Hsp27 is a target protein for KRIBB3.  
 
3.5.  Overexpression of HSP27 relieved cells from KRIBB3 inhibition 
 
It is important to prove not only that Hsp27 physically interacts with 
KRIBB3 but also that Hsp27 is functionally involved in KRIBB3–dependent 
inhibition of cell migration and invasion. To address the functional role of Hsp27 
during the KRIBB3-dependent inhibition, I tested whether overexpression of Hsp27 
could overcome KRIBB3-dependent inhibition of tumor invasion. For this, I 
constructed Hsp27-overexpressing MDA-MB-231 cell line by transfecting 
expression vector pcDNA3-Hsp27 to MDA-MB-231 cells. Hsp27 expressing stable 
cell lines were selected with G418 for 21 days, as described in Materials and 
Methods. Fig. 9A showed expression level of Hsp27 from vector or Hsp27 
transfected cell lines. Tumor invasion assay was performed in the presence or 
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absence of KRIBB3. When Hsp27 was overexpressed, KRIBB3-induced inhibition 
of invasion was significantly overcome (Fig. 9B). This result further supported that 
Hsp27 is a target protein of KRIBB3 in vivo. Fig. 9C is a representative membrane 
images after staining of migrated cells during the invasion assay. 
 
3.6.  Knockdown of Hsp27 protein by using siRNA inhibited cell migration 
 
To determine whether down expression of Hsp27 affect cell migration, I 
introduced Hsp27 siRNA into MDA-MB-231 cells. As shown in Fig. 10A, 
expression of Hsp27 was significantly eliminated from MDA-MB-231 cells after 
transfection of Hsp27 siRNA, indicating that my siRNA for MDA-MB-231 can 
target Hsp27 mRNA efficiently. Then, I analyzed migration of MDA-MB-231 cells 
after cells were treated with control siRNA, Hsp27 siRNA, or H2O. As expected, 
migration of MDA-MB-231 cells was inhibited by 60% when Hsp27 expression was 
abolished (Fig. 10B). More than 95% of MDA-MB-231 cells were transfected by 
control siRNA when fluorescence-tagged siRNA was used as a control (data not 
shown). The expression of actin was not affected by control siRNA or Hsp27 siRNA. 
 
3.7.  PKC, Src, and PI-3-kinase are important for MDA-MB-231 cell migration 
 In order to figure out what kinds of cellular signal pathways are involved in 
my assay system, I tested several known kinase inhibitors such as AG1478 for 
EGFR, wortmannin for PI-3-kinase, Y27632 for ROCK, PD98059 for MEK1, 
SB203580 for p38, rottlerin for PKC δ, or Bisindolylmaleimide I for PKC α, β, γ, δ. 
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As shown in Fig. 11, inhibitors of MEK, EGFR, p38 kinase, or ROCK did not 
inhibit migration of MDA-MBV-231 cells in my assay system. However, inhibitors 
of PKC, Src, and PI-3-kinase could block migration of MDA-MB-231 cells. This 
result implies that signaling of PKC, Src, and PI-3-kinase is important for MDA-
MB-231 cells to migrate toward serum and any inhibitor of these pathways should 
be detectable by my assay system. Among the candidate kinases, PKC has been 
known to phosphorylate Hsp27, an identified KRIBB3 binding protein. This leads us 
to explore the role of PKC during the cell migration. 
 
3.8. Treatment with PMA antagonizes KRIBB3-induced inhibition of migration 
 
Because PKC has been known to phosphorylate Hsp27 and its 
phosphorylation is involved in Hsp27-dependent actin dynamics, I analyzed effect 
of PKC activation on the cell migration in the presence or absence of KRIBB3. As 
shown in Fig. 12A, treatment with KRIBB3 inhibited migration of MDA-MB-231 
cells. However, co-treatment of PMA with KRIBB3 could relieve KRIBB3-
dependent inhibition of migration. This result suggested that activation of PKC 
could reverse KRIBB3 effects. Fig. 12B showed typical pictures of migrated cells in 
the membrane after staining during the migration assay.  In order to see the 
correlation between cell migration and phosphorylation of Hsp27, I analyzed 
phosphorylation of Hsp27 (Ser-78) by using a phospho-specific antibody for Hsp27. 
Consistent with previous report, phosphorylation of Hsp27 was significantly 
increased by PMA treatment (Fig. 12C). However, when cells were treated with 
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KRIBB3, PMA-induced Hsp27 phosphorylation was significantly decreased. These 
data indicated that KRIBB3 inhibited migration of MDA-MB-231 cells via blocking 
phosphorylation of Hsp27. In order to test specificity of KRIBB3 on Hsp27, I 
analyzed phosphorylation of other PKC substrate in the presence of KRIBB3. 
PLCβ3 is known substrate of PKC (Strassheim and Williams, 2000). If KRIBB3 
blocked phosphorylation of Hsp27 by direct binding to Hsp27 itself, KRIBB3 may 
not block phosphorylation of PLCβ3. As expected, KRIBB3 could not block PMA-
induced phosphorylation of PLCβ3, supporting that direct binding of KRIBB3 to 
Hsp27 is responsible for inhibition of phosphorylation of Hsp27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
4. Discussion 
 
 My first aim was identification of migration-specific genes that are 
involved in the regulation of cell migration. In order to identify migratory gene, I 
sought anti-migratory compounds by using cell-based screening. I excluded 
chemicals which showed growth inhibition. Whole cell based assay was preferred 
because of its ability to simultaneously assess multiple targets. From this, I 
identified “cell stoppers”, CAC-1098 and CBI-0997. These compounds can block 
cell migration without cytotoxicity. Among the identified chemicals, CBI-0997 has 
better drug-like structure and I decided to characterize it further. As a derivative of 
CBI-0997, KRIBB3 was synthesized by replacing bromide with methoxyl group. 
KRIBB3 has similar anti-migratory and anti-invasive activity as CBI-0997. 
One of the characteristic features of KRIBB3 treated cells was rounding of 
cell morphology in the early time point (within 5 min). This implies that KRIBB3 
may affect cytoskeleton. Because integrin is an important regulator for cytoskeleton 
and cell migration and FAK is a major downstream effector of integrin signaling, I 
examined whether FAK is inhibited by KRIBB3 or not. As shown in Fig. 7A, 
amount of phosphorylation of FAK was increased 1 hr after KRIBB3 treatment and 
reached maximum 3 h after the treatment.  Then, its phosphorylation was gradually 
decreased and reached basal level 24 h after the treatment. Therefore, it is unlikely 
that KRIBB3 inhibited cell migration through FAK inhibition.  
In order to know general properties of my migration assay system, I 
analyzed several inhibitors of kinases known to be involved in cell migration. From 
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this, I noticed that Src, PI-3-kinase, and PKC are important signaling kinases for 
migration of MDA-MB-231 cells (Fig. 11). Because p130Cas is a major substrate of 
Src (Sakai et al., 1994) and localized at focal adhesion, I tested whether KRIBB3 
inhibited phosphorylation of p130Cas. However, I could not detect any inhibition of 
p130Cas phosphorylation by KRIBB3 (Fig. 6B), suggesting that KRIBB3 did not 
inhibit Src kinase.  Next, I analyzed PI-3-kinase activity by measuring amount of 
phospho-AKT, an effector of PI-3-kinase. However, I could not see any decrease of 
amount of phospho-AKT (Fig. 7C). In contrast, I could see small increase of 
phospho-AKT.  This result implied that KRIBB3 did inhibit cell migration not 
through PI-3-kinase signaling.  
In order to study the effect of PKC activation on KRIBB3-dependent 
inhibition of cell migration, cells were treated with either PMA or KRIBB3 or both. 
As shown in Fig. 12A, treatment of MDA-MB-231 cells with PMA increased cell 
migration. In addition, KRIBB3-dependent inhibition of cell migration was 
significantly relieved by treatment of PMA. Therefore, I concluded that KRIBB3 
inhibited cell migration by blocking PKC-dependent signaling. 
The major technical challenge during phenotype-based screening is 
identification of target protein of bioactive molecule. Affinity chromatography can 
be a powerful method for target identification. However, this approach has its limits 
when chemical modification of the compound is not compatible with its biological 
activity. The synthesized biotinyl-KRIBB3 retained comparable anti-migratory 
activity (IC50 is 0.2 µM). Using bioactive biotinyl-KRIBB3, I identified Hsp27 as a 
direct target protein of KRIBB3 (Fig. 8). To exclude the possibility that Hsp27 is 
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non-specific binding partner, I synthesized biotinyl-KRIBB2, structural analogue of 
biotinyl-KRIBB3, and used it as a negative control. In addition, I carried out 
competition assay with free KRIBB3. As shown in Fig. 8D, a large molar excess 
amount of free KRIBB3 inhibited binding of Hsp27 to immobilized KRIBB3.  
Furthermore, I proved functional role of Hsp27 during the cell invasion and 
migration both by overexpressing Hsp27 and by knockdown of Hsp27 protein. As 
shown in Fig. 9, overexpression of Hsp27 antagonized KRIBB3-dependent 
inhibition of cell invasion and knockdown of Hsp27 protein by Hsp27 siRNA 
mimicked the KRIBB3 effect, inhibition of cell migration. 
Hsp27 has been recognized as a potent regulator of cytoskeleton dynamics, 
actin microfilaments. Actin cytoskeleton is modulated by both the spatial 
arrangement as well as the polymerization dynamics of its different elements (Liang 
and MacRae, 1997). Hsp27 stabilizes actin filaments in a yet undefined manner 
resulting in increased resistance to stresses and this function is regulated by the 
phosphorylation of Hsp27. Phosphorylation of Hsp27 is catalyzed by MAKPAP 
kinase 2 and 3 (Landry et al., 1992; Ludwig et al., 1996; Stokoe et al., 1992), PKC 
(Maizels et al., 1998), PKD (Doppler et al., 2005), and cGMP-dependent protein 
kinase (Butt et al., 2001). Because KRIBB3 binds to Hsp27 (Fig. 8C) and PKC is 
important kinase for migration of MDA-MB-231 cell (Fig. 11) and activation of 
PKC by PMA antagonizes KRIBB3-dependent inhibition of cell migration (Fig. 
12A), and KRIBB3 inhibits PKC-dependent phosphorylation of Hsp27 (Fig. 12C), it 
is highly likely that KRIBB3 specifically binds to Hsp27 and blocks PKC-dependent 
HSP27 phosphorylation and PKC-dependent migration. The specificity of KRIBB3 
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on HSP27 was further supported by the fact that KRIBB3 could not block PMA-
induced phosphorylation of PLCβ3, another PKC substrate (Fig. 12C). To my 
knowledge, the KRIBB3 is the first inhibitor of Hsp27 and it will be useful to 
analyze Hsp27 functions in cell.  
Higher levels of Hsp27 expression are reported in variety different cancers 
including breast (Love and King, 1994; Oesterreich et al., 1993) prostate (Cornford 
et al., 2000) gastric (Chen et al., 2004; Ehrenfried et al., 1995) and ovarian (Langdon 
et al., 1995) cancer. In addition, several studies point to the ability of Hsp27 to 
increase the metastatic potential of tumor cells in nude mice as well as enhancing 
their resistance to therapy (Blackburn et al., 1997) (Katoh et al., 2000). Interestingly, 
Blackburn and his colleagues reported that murine Hsp25 but not human Hsp27 
enhanced tumor growth in nude mice. I do not know why murine Hsp27 and human 
Hsp27 showed such a difference. One possible explanation is cell type difference. 
Blackburn and his colleagues used murine L929 fibrosarcoma cells and I used 
human MDA-MB-231 epithelial carcinoma cells.  
Recently, Yarrow and his colleagues reported inhibitor of cell migration 
from screening of library using wound healing assay (Yarrow et al., 2005). Using 
automated microscopy, they screened library of 16,000 chemicals and found one, 3-
(4-pyridyl) indole. This inhibitor blocked cell migration via blocking Rho-kinase. 
However, my screening system could not identify 3-(4-pyridyl) indole-like 
compounds because migration of MDA-MB-231 cells is not inhibited by Rho kinase 
inhibitor, Y27632, in my assay system (Fig. 11). Similarly, natural product 
(migrastatin) from Streptomyces was shown to inhibit cell migration (Nakae et al., 
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2000). In addition, more potent analogs of migrastatin were reported (Njardarson et 
al., 2004; Shan et al., 2005). Migrastatin was reported to exert its effect by inhibiting 
Rac activation. However, it is not known whether migrastatin binds directly to Rac 
or its upstream molecule(s) and target identification remains to be solved. 
Currently, I do not know the binding constant of KRIBB3 to the Hsp27 or 
binding pocket in the Hsp27. The IC50 of KRIBB3 for migration was 50 nM, 
suggesting that KRIBB3 has high specific affinity to the target protein, Hsp27. This 
high affinity and relatively high abundance of Hsp27 may contribute this success of 
affinity chromatography for target identification. In addition, it will be very 
important to identify binding pocket of Hsp27 for KRIBB3 in order to optimize 
KRIBB3 structure for drug development in the future. 
  Overall, I identified Hsp27 and KRIBB3 as a migratory gene and its 
inhibitor, respectively, by using chemical genomic approach. The cellular basis for 
this effect rests on the inhibition of Hsp27 phosphorylation which regulates cell 
migration. 
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Fig. 2. Schematic diagram of method for screening of small molecules that 
affect cell migration. Chemical library compounds were added into bottom 
chamber with 10% of fetal bovine serum. Cancer cells were loaded into top chamber 
and incubated for 18 h. Migrated cells were stained and counted under the light 
microscope. 
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KRIBB2                   KRIBB3 
 
 
Fig. 3. Structure of small molecules shown are the structure of compounds CAC-
1098 (aurintricarboxylic acid), CBI-0997 (5-(2, 4-dimethoxy-5-ethylphenyl)-4-(4-
Bromophenyl) isoxazole), and KRIBB3 (5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-
(4-methoxyphenyl) isoxazole) that inhibit cell migration. KRIBB2 (4-ethyl-5-
methoxy-2(3-methyl-4-phenylisoxazole-5-yl) phenol) is an analogue of KRIBB3 
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Fig. 4. The effects of identified inhibitors on migration and proliferation of 
tumor cells. A, MDA-MB-231 cells were treated with different concentrations of 
inhibitors or with vehicle solvent (1% DMSO), and the cell migration assays were 
performed as described under “Materials and Methods.” The mean and standard 
deviation of relative migration rate (normalized to vehicle treated cell as 100) from 
three independent experiments are shown. B, MDA-MB-231 cells were treated with 
different concentrations of inhibitors or with vehicle solvent (0.1% DMSO) and 
viability were determined by using WST-1 at 48 h after treatment. The results are 
expressed as relative value to the vehicle treated cells 
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Fig. 5. The effects of identified inhibitors on invasion of tumor cells. A and B, 
MDA-MB-231 cells were treated with different concentrations of CAC-1098 and 
KRIBB3 or with vehicle solvent (1% DMSO), and the cell invasion assays were 
performed as described under “Materials and Methods.” The mean and standard 
deviation of relative invasion rate (normalized to vehicle treated cell as 100) from 
three different fields are shown. 
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Fig. 6. Time course analysis of cell morphology and phosphorylation of after 
KRIBB3 treatment A, MDA-MB-231 cells were treated with 10 µM KRIBB3 or 
0.1% of DMSO and incubated for different times as indicated. Cell morphology was 
imaged by Nikon microscope. B, MDA-MB-231 cells were treated with 10 µM 
KRIBB3 or 0.1% of DMSO and the lysates were prepared with RIPA buffer. 40 µg 
of lysate were resolved by SDS-PAGE and immunoblotted with PY-20 antibody 
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Fig. 7. Time course analysis of phosphorylation of FAK, p130cas, and AKT after 
KRIBB3 treatment A and B, 400 µg of lysate treated with 10 µM KRIBB3 were 
immunoprecipitated with FAK antibody or p130Cas antibody, respectively, and 
protein G-agarose beads, and precipitants were resolved by SDS-PAGE after 
washing three times and immunoblotted with PY-20 antibody (A and B, left panels), 
anti-FAK (A, right panels) antibody or anti-p130Cas antibody (B right panels). C, the 
same whole cell lysates (WCL) were resolved by SDS-PAGE and immunoblotted 
with anti-phospho-AKT (left panels) or anti-AKT (right panels) antibody. 
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Fig. 8. Identification of KRIBB3 binding proteins. 10 mg of total protein was 
incubated with 10 µM of biotin or biotinyl-KRIBB3 and bound proteins were 
applied top column with NeutrAvidin beads. The proteins were eluted with biotin 
and analyzed by 10% SDS-PAE. Compared with biotin-treated sample, biotinyl-
KRIBB3-treated sample has one unique band of 30-kDa. The 30-kDa protein was 
eluted and sent for sequencing. A, Peptides were sequenced by electrospray 
ionization quadrupole time-of-flight tandem mass spectrometry, and internal 
sequences were searched using the Mascot database. B, The Hsp27 has 205 amino 
acids. Peptides matching the Hsp27 protein are underlined and in boldface. C, 10 mg 
of total protein was incubated with 10 µM of biotin, biotinyl-KRIBB2, or biotinyl-
KRIBB3, and bound proteins were applied to a column with NeutrAvidin beads. The 
eluted proteins were resolved with by 10% SDS-PAGE and immunoblotted with 
anti-Hsp27 specific antibody. D, shown is the competition of KRIBB3 with biotinyl-
KRIBB3 for binding to the Hsp27 protein. DMSO, dimethyl sulfoxide. 
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Fig. 9. Overexpression of Hsp27 can antagonize KRIBB3-induced inhibition of 
invasion A, shown are the results from Westen blot analysis of Hsp27 expressions 
in MDA-MB-231 (Wild-type), pcDNA3-transfected, and pcDNA3-Hsp27-
transfected (Hsp27) cells. Whole cell lysates (10 µg) were separated by 12.5% SDS-
PAGE and blotted with anti-Hsp27 antibody. B, Vector- or Hsp27-overexpressing 
MDA-MB-231 cells were treated with 0.1 µM of KRIBB3 or with vehicle solvent 
(1% DMSO), and the cell invasion assays were performed as described under 
“Materials and Methods.” The mean ± S.D. of the relative invasion rate 
(normalized to vehicle-treated cell as 100%) from three different fields are shown. *, 
P<0.01 (Vector treated cells with KRIBB3 versus Hsp27-treated cells with 
KRIBB3). C, invading cells were imaged using a Nikon microscope after staining.  
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Fig. 10. Knockdown of Hsp27 protein can mimic KRIBB3 effect. A, shown are 
the results from Western blot analysis of Hsp27 expressions in MDA-MB-231(Wild-
type), or control siRNA-transfected (Con siRNA), and Hsp27 siRNA-transfected 
(Hsp27 siRNA) cells. Whole cell lysates (30 µg) were separated by 12.5% SDS-
PAGE and blotted with anti-Hsp27 antibody. B, MDA-MB-231 cells were 
transfected with control (con) siRNA or Hsp27 siRNA, and the migration assay was 
performed as described under “Materials and Methods.” The mean ± S.D. of the 
relative migration rate (normalized to control siRNA as 100%) from three different 
fields are shown. *, P<0.01 (control siRNA versus Hsp27 siRNA as 100%). C, 
migrated cells were imaged using a Nikon microscope after staining.  
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Fig. 11. Migration of MDA-MB-231 is decreased by inhibitor of PKC, PI3K, 
and Src kinase. MDA-MB-231 cells were treated with rottlerin (5 µM), PD98059 
(40 µM), bisindolymaeimide I (BIS; 5 µM), Y27632 (10 µM), wortmanin (10 µM), 
SB203580 (10 µM), AG1478 (10 µM), or PP2 (50 µM) and cell migration assays 
were performed as described under “Materials and Methods.” The means The mean 
± S.D. of the relative migration rate (normalized to vehicle-treated cells as 100) 
from three independent experiments are shown. 
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Fig. 12. KRIBB3-dependent inhibition of cell migration is antagonized by PKC 
activation. A, MDA-MB-231 cells were serum-starved overnight and then subjected 
to the cell migration assay using Transwells at different concentrations of KRIBB3 
as indicated and/or PMA (0.1 µM). The means The mean ± S.D. of the relative 
migration rate (normalized to vehicle-treated cells as 100) from three independent 
experiments are shown. B, the cells were treated with KRIBB3 at the indicated 
concentration and/or PMA (0.1 µM) and incubated for 4 h, and the migrated cells 
were fixed, counted, and photographed. C, MDA-MB-231 cells were treated for 4 h 
with different concentrations of KRIBB3 and/or PMA (0.1 µM) or with vehicle 
solvent (0.1% DMSO), and lysates were prepared with RIPA buffer. 40 µg of 
lysates were resolved by SDS-PAGE and blotted with anti-phospho-Hsp27, anti-
Hsp27, anti-phosphorylated phospholipase Cβ3 (anti-phospho-PLCβ3), anti-
phospho-PKCμ, or anti-actin antibody. 
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Part Ⅱ 
 
KRIBB3, a Novel Microtubule Inhibitor, Induces Mitotic Arrest and 
Apoptosis in Human Cancer Cells 
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Abstract 
 
KRIBB3, (5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl) 
isoxazole) inhibited cancer cell growth in vitro and in vivo. Flow cytometry study 
showed that KRIBB3 caused cell cycle arrest at G2/M phase and apoptosis. This was 
confirmed by detecting accumulation of Cyclin B1 and cleavage of poly (ADP-
ribose) polymerase (PARP). While transient inhibition by KRIBB3 leaded to 
reversible mitotic arrest, prolonged exposure to the KRIBB3 induced apoptosis. Co-
immunoprecipitation assay showed that KRIBB3 initially induced association of 
inhibitory Mad2 with p55CDC (mammalian homologue of CDC20), activator of 
APC/C (anaphase-promoting complex/cyclosome), suggesting that mitotic spindle 
checkpoint was activated by KRIBB3. However, this inhibitory complex of Mad2 
with p55CDC was gradually decreased 24 h after KRIBB3 treatment and was hardly 
detectable after 48 h, indicating slippage of mitotic checkpoint. Consistent with 
these observations, KRIBB3 activated the mitotic spindle checkpoint by disrupting 
microtubule cytoskeleton. KRIBB3 was proven to be a tubulin inhibitor using in 
vitro polymerization assays and in vivo indirect immunofluorescence staining. The 
temporal pattern of Bax activation by KRIBB3 was similar to PARP cleavage, 
suggesting that Bax is a mediator of KRIBB3-dependent apoptosis. Furthermore, 
when KRIBB3 was administered intraperitoneally into nude mice at 50 mg/kg or 
100 mg/kg, it inhibited 49.5% or 70.3% of tumor growth, respectively. These results 
suggest that KRIBB3 is a good drug candidate for cancer therapy. 
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Introduction 
 
Chemicals that interfere with cell cycle progress have attracted much 
attention in cancer research because they can inhibit the proliferation of cancer cells. 
Among various anticancer drug targets known to date, microtubules are one of the 
most successful targets for cancer therapy (Zhou and Giannakakou, 2005). 
Microtubules are the principal components of the cytoskeletal system that takes part 
in intracellular transport, motility, architecture, and alignment and separation of 
chromosomes in meiosis and mitosis (Jordan and Wilson, 2004). Microtubules are 
polymeric structures composed of two structurally similar protein subunits, namely 
α– and β–tubulin, arranged head-to-tail to form a linear protofilament. During 
mitosis, microtubules undergo rapid polymerization and depolymerization to enable 
movement of the chromosomes. Mitotic checkpoint proteins monitor lack of tension 
or attachment between the kinetochores and microtubules. 
Traditional antimitotic drugs produce “unattached” kinetochores in mitosis 
by altering microtubule dynamics and cause long-term mitotic arrest (Jordan and 
Wilson, 2004; Mollinedo and Gajate, 2003). Vinca alkaloids, inhibiting microtubule 
polymerization, have been used in the treatment of cancer over 30 years (Jordan et 
al., 1991). Unlike vinca alkaloids, taxanes promote tubulin polymerization, stabilize 
microtubules, and thereby inhibit microtubule dynamics, causing abnormal mitotic 
spindle and mitotic arrest (Manfredi and Horwitz, 1984; Schiff et al., 1979). 
Although the Vinca alkaloids and the taxanes are effective in the treatment of cancer, 
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their potential is limited by the appearance of drug resistant cancer cells during the 
cancer treatment (Dumontet and Sikic, 1999). One mechanism leading to drug 
resistance is mediated by overexpression of efflux pump, namely the p-gp170 
(Fardel et al., 1996) and the MRP (Cole and Deeley, 1998). These efflux pumps are 
able to reduce the intracellular concentration of taxanes or Vinca alkaloids to a less 
toxic level. The link between prolonged mitotic checkpoint activation and cell death 
has not been well studied. 
The mitotic spindle checkpoint is the major cell cycle control mechanism in 
mitosis (for review, (Bharadwaj and Yu, 2004; Jordan and Wilson, 2004; Weaver 
and Cleveland, 2005)). Mitotic progression is controlled by APC/C (anaphase-
promoting complex/cyclosome), a multi-subunit E3 ubiquitin ligase (Peters, 2006). 
In order to recognize and interact with mitotic substrates, APC/C requires a specific 
factor CDC20 (cell-division-cycle 20 homologue). Genetic and biochemical studies 
have suggested that the most downstream event in checkpoint regulation is the 
inhibition of CDC20. Inhibition of CDC20 is accomplished by the mitotic 
checkpoint complex which is composed of Mad2, BubR1, Bub3, and CDC20 
(Sudakin et al., 2001; Tang et al., 2001). Substrates that are targeted for degradation 
by APC/C include the master regulator of mitosis, Cyclin B1, as well as securin. 
These proteolytic events are controlled by mitotic checkpoint, the primary cell-cycle 
control mechanism in mitosis. 
The signal generators of the mitotic checkpoint are unattached kinetochores 
which recruit mitotic checkpoint components and convert these in a form that 
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inhibits the CDC20-dependent APC/C activity (Weaver and Cleveland, 2005). The 
first checkpoint components were identified by genetic screening in yeast and were 
named Bub (budding uninhibited by benzimidazole) 1-3, Mad (mitotic arrest 
deficient) 1-3, and Mps 1 (monopolar spindle 1) (Hoyt et al., 1991; Li and Murray, 
1991; Weiss and Winey, 1996). The vertebrate mitotic checkpoint requires the 
kinase BubR1 (a hybrid of Mad3 and Bub1), the ZW10-ROD-zwilch complex, 
CENPE (centromere protein E), and MAPK (mitogen activated protein kinase) 
(Abrieu et al., 2000; Chan et al., 2000; Chan et al., 1999; Mao et al., 2003). 
Following nuclear envelop breakdown, the checkpoint proteins are recruited to 
unattached kinetochore, protein-rich structures of chromosomes. Unoccupied 
kinetochores generate a “wait signal” to inhibit the anaphase promoting complex 
(Kops et al., 2005; Mao et al., 2003). Direct binding of CENPE to BubR1 activates 
the BubR1 kinase activity required for the recruitment of a stable Mad1-Mad2 
heterodimer, which, in combination with other checkpoint proteins, modifies Mad2 
into an active conformation. Activated Mad2 and/or BubR1 tightly associate with 
CDC20, preventing it from activating the APC/C, inhibiting degradation of Cyclin 
B1. For release of mitotic checkpoint, microtubule capture by CENPE is the most 
important signal transduction event because it shutdown production of the inhibitory 
complexes. 
Although the capacity to carry out apoptosis is inherited to all cells, their 
susceptibility varies markedly and is influenced by external and internal events (Raff, 
1992). Members of the Bcl-2 family of proteins play crucial roles in the regulation 
of apoptosis through controlling mitochondria function and releasing proapoptotic 
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proteins from mitochondria. Because mitochondria interact with microtubules, it is 
likely that mitochondria may connect microtubule damage to the apoptotic 
machinery, acting as appropriate and timing switches for the onset of apoptosis. In 
mammals, Bcl-2 has over 20 relatives, all of which share at least one of four 
conserved motifs known as the Bcl-2 homology (BH) domain, termed BH1, BH2, 
BH3, and BH4 (Adams and Cory, 1998). Bcl-2 overexpression suppresses the 
apoptotic response induced by distinct microtubule-active drugs, without affecting 
their actions on microtubules and on cell cycle arrest at G2/M (Gajate et al., 2000; 
Tang et al., 1994). Bim (Bcl-2 interacting mediator of cell death) (Puthalakath et al., 
1999) and Bmf (Bcl-2 modifying factor) (Puthalakath et al., 2001) are important 
linkers of cytoskeleton and apoptotic machinery since they are indirectly sequestered 
by microtubule (Bim) or actin (Bmf) cytoskeleton. Apoptotic stimuli lead to the 
release of Bim from microtubules, and Bim is therefore freed to translocate to 
mitochondria where it binds Bcl-2 and Bcl-XL and promote apoptosis through 
neutralization of the antiapoptotic activity of Bcl-2 and Bcl-XL by forming Bim/Bcl-
2 or Bim/Bcl-XL heterodimers (Puthalakath et al., 1999), or through additional 
mechanisms, including Bax activation (Marani et al., 2002). 
In previously part I, KRIBB3 was reported to inhibit tumor cell migration 
and invasion at 0.1-1 µM. However, it inhibited proliferation of MDA-MB-231 with 
a GI50 of > 25 µM, where GI50 is the concentration of an inhibition at which 50% 
inhibition of the cell growth is seen. This indicates that KRIBB3 significantly 
inhibits cell migration without cytotoxic problem. Using affinity chromatography, 
Hsp27 was identified as a molecular target of KRIBB3. Several other studies point 
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to the ability of Hsp27 to increase the metastatic potential of tumor cells in nude 
mice as well as enhancing their resistance to therapy (Blackburn et al., 1997; Katoh 
et al., 2000). Higher levels of Hsp27 expression are commonly detected in variety 
different cancers including breast (Love and King, 1994; Oesterreich et al., 1993), 
prostate (Cornford et al., 2000), gastric (Ehrenfried et al., 1995), and ovarian (Arts et 
al., 1999; Langdon et al., 1995) cancer.  
Here we report the biological properties of KRIBB3 that displayed strong 
antimitotic activity against cancer cells. KRIBB3 exerted its antiproliferative activity 
through inhibition of tubulin polymerization and activating mitotic spindle 
checkpoint. In addition, KRIBB3 is not a substrate of p-gp170 and retains its activity 
in cell lines with MDR. When KRIBB3 was administered into nude mice, it 
significantly inhibited tumor growth compared with control mice, supporting its 
anticancer activity in vivo. 
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2. Materials and Methods 
 
2.1. Materials  
 
Rabbit polyclonal anti-phospho-Histone-H3 (Ser 10) antibody was 
purchased from Upstate Biotechnology. Antibodies against Hsp27 and PARP were 
purchased from Cell Signaling. Antibodies against Bax, Mad2, and BubR1 were 
purchased from BD biosciences (San Jose, CA). Antibodies of Cyclin B1, p55CDC, 
and actin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
Monoclonal anti-Bax 6A7 antibody was purchased from Sigma (St. Louis, MO). 
Chemicals used in these experiments were purchased from Sigma Chemical (St. 
Louis, MO) and Calbiochem (San Diego, CA). Monoclonal anti-α-tubulin was 
purchased from Molecular Probes (Invitrogen; Carlsbad, CA). KRIBB2 (4-ethyl-5-
methoxy-2(3-methyl-4-phenylisoxazole-5-yl) phenol) and KRIBB3 (5-(5-ethyl-2-
hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl) isoxazole) were synthesized in my 
laboratory.  
 
2.2. Cell culture 
 
The cancer cell lines were obtained originally from ATCC. HCT-116 (human 
colon cancer cell line), HCA-7 (human breast cancer cell line), and SK-OV-3 
(human ovarian cancer cell line) were maintained in McCoy’s 5A (Invitogen) 
medium supplement with penicillin (50 units/ml)/streptomycin (50 µg/ml). MDA-
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MB-231 (human breast cancer cell line), HT-29, HCT-15, SW620 (human colon 
cancer cell line), NCI-H23 (human non small lung cancer cell line), DU-145, and 
PC-3 (human prostate cancer cell line) were maintained in RPMI 1640 (Gibco/BRL). 
A549 (human non small lung cancer cell line) and HeLa (human cervical 
adenocarcinoma cell line) were maintained in Dulbecco's modified Eagle medium 
(Gibco/BRL). All culture media were supplemented with 10% heat-inactivated fetal 
bovine serum (Gibco/BRL). Cell cultures were maintained at 37℃  under a 
humidified atmosphere of 5% CO2 in an incubator. 
 
2.3. Cell proliferation assays  
 
Proliferation assay was done, as described previously (Han et al., 2004). 
Briefly, cells (6,000 cells) were seeded into 96 well plates in McCoy’s 5A media 
containing 10% FBS. After 20-24 h, cells were replenished with fresh complete 
medium containing either a test compound or 0.1% DMSO. After incubation for 48 
h, cell proliferation reagent WST-1 (Roche Applied Science) was added to each well. 
The amount of WST-1 formazan produced was measured at 450 nm using an ELISA 
Reader (Bio-Rad, CA). 
 
2.4. Western Blotting and immunoprecipitation 
 
Lysates were prepared using RIPA buffer (50 mM Tris HCl, pH 7.4, 150 mM 
NaCl, 1% Triton X-100, 0.1% SDS, 5mM EDTA, 30 mM Na2HPO4, 50 mM NaF, 
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0.5 mM NaVO4, 2mM PMSF, and 1% aprotinin), as described previously (Han et al., 
2004). A 20~40 µg protein was resolved by SDS-PAGE and transferred to PVDF 
membrane (Roche, Germany). Membrane was blocked with 1% Western Blocking 
Reagent (Roche, Germany) in TBS-T (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
0.05% Tween 20). The primary antibodies were used as recommended by the 
manufactures. The secondary antibodies used were horseradish peroxidase-
conjugated goat anti-rabbit or anti-mouse IgG from Jackson immunology. 
Membrane was incubated with primary antibody for 2 h at room temperature, 
washed 3 times with TBS-T, and visualized with chemiluminescent β-peroxidase 
reagents (Roche, Germany). For immunoprecipitation, 400 µg of lysates were 
incubated with primary antibody for 2 h at 4  in rotary shaker and then, 40 µl of ℃
protein G-agarose beads were added. After 1 hr, beads containing lysates were 
centrifuged and washed 3 times with lysis buffer. Beads-bound proteins were 
resolved by SDS-PAGE and immunoblotted using specific antibody. 
 
2.5.  siRNA Transfection   
 
The human Hsp27 small interfering RNA (siRNA) duplex (5’-
GUCUCAUCGGAUUUUGCAGC-3’) was purchased from Bioneer, Inc. (Daejeon, 
KOREA). Cells plated at a density of 1.5105 cells per well in six-well plates were 
transfected with 50 nM or 100 nM of Hsp27 specific and control siRNA 
oligoduplexes after a preincubation for 20 min with Oligofectamine in serum free 
OPTI-MEM (Invitrogen). Four hours after the beginning of the incubation, the 
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medium was added with the McCoy’s 5A containing 30% of serum (without 
antibiotics), making final concentration of 10% of serum. 48 hours after transfection, 
cells were collected and used for cell cycle analysis or for preparation of whole cell 
lysates. 
 
2.6. Cell synchronization  
 
For synchronization at metaphase, cells were treated with nocodazole (1 µM) 
at 37  for 15 ℃ h. After treatment, metaphase cells were collected by gentle shake-off 
method, centrifuged at 300  g for 5 min at room temperature, and washed twice 
with fresh medium. To relieve cells from the mitotic phase arrest, they were replated 
in a 100-mm cell culture dish (1106 cells/dish) and incubated at 37  in fresh ℃
medium for various time periods.  
 
2.7. Cell cycle analysis  
 
Cell cycle was analyzed, as described previously (Han et al., 2004). Briefly, 
cells were trypsinized from the culture dish. After centrifugation at 300  g for 5 
min at room temperature, the supernatant was removed. The cells were then washed 
twice with phosphate-buffered saline (PBS; 8 g of NaCl, 0.2 g of KCl, 1.44 g of 
Na2HPO4·7H2O, 0.24 g of KH2PO4·H2O/liter, adjusted to pH 7.2) solution and fixed 
with 5 ml of ice-cold 70% ethanol overnight. Fixed cells were harvested by 
centrifugation at 300  g for 5 min at room temperature and washed twice with PBS. 
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Collected cells were suspended in PBS (100 µl/1  105 cells) and treated with 100 
µg/ml RNase A at 37℃ for 30 min. Propidium iodide was then added to final 
concentration of 50 µg/ml for DNA staining, and 20,000 fixed cells were analyzed 
on FACScalibur (BD Biosciences). Cell cycle distribution was analyzed using the 
Modifit’s program (BD Biosciences).  
 
2.8. Tubulin polymerization assay  
 
For the detection of polymerization of tubulin/microtubule, The 
CytoDYNAMIX Screen 01 kits were purchased form Cytoskeleton Inc. (Denver, 
CO). Tubulin proteins (>97% purity) were suspended (300 µg/sample) with 100 µl 
of G-PEM buffer (80 mM PIPES, 2 mg MgCl2, 0.5 mM EGTA, 1.0 mM GTP, pH 
6.9) plus 5% glycerol in the 0.1% DMSO or test compounds at 4 . Then the sample ℃
mixture was transferred to the prewarmed 96-well plate, and polymerization of 
tubulin was measured by the change in absorbance at 340 nm every 1 min for 70 
min (Wallac victor2; PerkinElmer, Inc., Wellesley, MA) at 37 .℃  
 
2.9. Immunofluorescence Microscopy 
 
HCT-116 cells were plated on 18 mm coverslip that was coated with 50 
mg/ml of Poly-L-Lysine. Cells were incubated in a 37℃ incubator to allow cells to 
attach and spread. At the end of incubation, the cells were fixed with 3% 
formaldehyde for 10 min, washed three times with PBS for 5 min, permeabilized 
 54 
with 0.5% Triton X-100 for 5 min, washed three times, and stained with primary 
antibodies (α-tubulin (1: 50)) for 1 hr at room temperature. After washing three 
times with PBS, the bound mouse IgG was detected with Texas Red-conjugated 
anti-mouse (1: 100) and counterstained with 1 µg/ml of DAPI (4’, 6-diamidino-2-
phenylindole) in PBS for 1 hr at room temperature. Image of stained cells was 
examined under a Zeiss LSM 510 META confocal microscope (Carl Zeiss, Inc., 
Thornwood, NY) 
 
2.10. Detection of Bax conformational change (activation)  
 
Metaphase synchronized cells were treated with 0.1% DMSO or 1 µM of 
KRIBB3. The method was modified from the previous description (Tao et al., 2005). 
In brief, cells were collected and lysed with Chaps lysis buffer (10 mM Hepes (pH 
7.4), 150 mM NaCl, and 1% Chaps). Cell lysates containing 500 µg proteins were 
incubated with anti-Bax 6A7 monoclonal antibody for 3 h at 4  in rotary shaker ℃
and then, 40 µl of protein G-agarose beads were added. After 2 h, beads containing 
lysates were centrifuged and washed 3 times with Chaps lysis buffer. Beads-bound 
proteins were resolved by SDS-PAGE and immunoblotted using anti-Bax 
monoclonal antibody (BD bioscience). 
 
2.11. Nude mouse xenograft assay.  
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Female inbred specific-pathogen-free (SPF) BALB/c nude mice, 7 weeks old, 
were obtained from Charles River Co. (Japan), and housed in sterile conditions 
under 12 h light/dark cycles, and fed food and water ad libitum. For the evaluation 
of in vivo anti-tumor activity of KRIBB3, HCT-116 cells (0.3 ml of 3ⅹ106 cells/ml) 
were implanted subcutaneously into the right flank of the mice on day 0. KRIBB3 or 
doxorubicin was dissolved in 0.5% Tween 80 and was daily administered 
intraperitoneally for 16 days at a concentration 50 or 100 mg/kg for KRIBB3 or 2 
mg/kg for doxorubicin. The amount of dosage was 0.2 ml per 20 g body weight of 
animals. Tumor volumes were estimated as; length (mm) ×width (mm) ×height 
(mm)/2. To determine the toxicity of the compound, the body weight of tumor-
bearing animals was measured. On day 16, the mice were sacrificed and the tumors 
were weighed. 
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3. Results 
 
3.1. Inhibition of tumor cell growth by KRIBB3 
 
To determine the effect of isoxazoles on growth of cancer cells, HCT-116 
colon cancer cells were treated with compounds at different concentrations (0-100 
µM) for 48 h (Fig 13). KRIBB2 is an inactive structural analogue of KRIBB3. 
KRIBB3 exhibited a dose dependent inhibition of cell growth in a broad range of 
concentrations and the GI50 value of KRIBB3 for in vitro growth inhibition was 
approximately 0.35 µM, where GI50 is the inhibitor concentration at which 50% 
inhibition of cell growth is seen. 
Failure in cancer chemotherapy is often related to multidrug resistance 
(MDR). Therefore, I tested whether MDR1 overexpression confers resistance to 
KRIBB3. Paclitaxel and vinblastin are the most widely used antimitotic cancer drugs, 
and are substrates of P-glycoprotein (MDR1). Therefore, I used these chemicals as 
positive compounds for MDR1. HCT-15 is an MDR1 overexpressing colorectal 
carcinoma. As expected, HCT-15 has profound resistance to paclitaxel (53-fold), 
vinblastin (11-fold), and colchicines (4-fold) compared with HCT-116. In contrast, 
KRIBB3 is equally potent toward HCT-116 and HCT-15 (Fig. 14 A and B), 
suggesting that KRIBB3 can be effective against MDR1-overexpressing drug-
resistant cells. 
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Similarly, the effect of KRIBB3 on the proliferation of various tumor cell 
lines was analyzed (Table 1). Because more than 50% of human cancers have 
mutated p53, which is known to be an important regulator of cell cycle progression 
and apoptosis, I chose to study both p53 wild type and p53-deficient cancer cell 
lines. Fortunately, KRIBB3 was able to exert its inhibitory activity in a p53-
independent pathway, as shown by its similar effects on the p53 expressing and 
deficient cell lines. 
   
3.2. Inhibition of Hsp27 does not block tumor cell growth 
 
Previously, I reported that KRIBB3 inhibited tumor cell migration by 
blocking PKC-dependent phosphorylation of Hsp27 through its direct binding to 
Hsp27. To determine whether inhibition of Hsp27 affect cell proliferation, I 
introduced Hsp27 siRNA into HCT-116 cells. As shown in Fig. 15A, expression of 
Hsp27 was largely eliminated from HCT-116 cells after transfection of Hsp27 
siRNA, indicating that siRNA can target Hsp27 mRNA efficiently in HCT-116 cells. 
Next, I analyzed the proliferation of HCT-116 cells after the cells were treated with 
control siRNA, Hsp27 siRNA, or H2O. Surprisingly, there was no detectable 
inhibition of proliferation by Hsp27 siRNA transfection (Fig. 15B). This result 
implies that KRIBB3 inhibits the proliferation of HCT-116 cells in a Hsp27-
independent manner. In addition, knockdown of Hsp27 using siRNA did not affect 
the HCT-116 cell cycle (Fig. 15C). 
 58 
3.3. KRIBB3 arrests cells in the G2/M phase 
 
Because KRIBB3 inhibited cancer cell growth, I analyzed the effect of 
KRIBB3 on the cell cycle profile. HCT-116 cells were treated with 1 µM of 
KRIBB3 and harvested at 0, 1, 3, 6, 12, 24, and 48 h after treatment and analyzed 
with a FACScalibur. When HCT-116 cells were treated with KRIBB3, an increase 
in the proportion of G2/M phase cells could be detected (Fig 16A and B). Seventy 
percent of cells were arrested at the G2/M phase checkpoint 12 h after treatment. 
Because KRIBB3 arrested the cell cycle in the G2/M phase, we used the well known 
antimitotic compound nocodazole as a control for further study. Treatment with 
nocodazole showed a similar effect on the cell cycle profile of HCT-116 cells. In 
addition, when DU-145 cells were treated with KRIBB3, cell cycle arrest could be 
detected at the G2/M phase (Fig. 23). Interestingly, treatment of asynchronous HCT-
116 cells with KRIBB3 resulted in the accumulation of cells with a hyperploid DNA 
content (>4 N) (Fig. 16C). Thirty-seven percent of cells became hyperploid (>4 N) 
48 h after KRIBB3 treatment. Similarly, 36% of nocodazole-treated cells were 
hyperploid. This result suggests that KRIBB3 first arrested cell cycle and then 
underwent mitosis to become hyperploid. Cell cycle arrest in the G2/M phase was 
confirmed by detecting G2/M phase-specific accumulation of Cyclin B1 and 
phosphorylation of Histone H3 (Ser10) (Fig. 16D). The Cyclin B1 protein levels 
increased after KRIBB3 treatment and remained elevated for 48 h. Similarly, 
phosphorylation of Histone H3 (Ser10) increased after KRIBB3 treatment and 
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remained elevated for 24 h. However, phosphorylation of Histone H3 (Ser 10) 
decreased to its basal level after 48 h. The temporal patterns of Cyclin B1 
accumulation and Histone H3 phosphorylation are consistent with cell cycle arrest at 
the G2/M phase as shown in Fig. 16. 
In order to determine whether KRIBB3-treated cells were blocked at the 
G2 phase or at the mitotic phase, cells were analyzed for progression from mitotic 
arrest. To synchronize cells in mitosis, HCT-116 cells were treated with 1 µM 
nocodazole for 15 h. After collection, synchronized mitotic cells were replated in 
medium containing DMSO or KRIBB3. Cells were collected at the time indicated, 
and the profile of the cell cycle was analyzed by FACS. As shown in Fig. 17A, 
HCT-116 cells were released from a nocodazole induced mitotic phase arrest after 
replating cells in the medium with DMSO. However, addition of KRIBB3 (Fig. 
17A) into replating medium did not result in the release of mitotic phase arrested 
cells. These results suggest that KRIBB3 arrested the cell cycle at the same mitotic 
phase as nocodazole. 
By treating with 1 µM of KRIBB3 for 15 h, HCT-116 cells were 
synchronized to mitotic phase. After collection, synchronized mitotic cells were 
replated in the medium with DMSO or nocodazole. As shown in Fig. 17B, addition 
of nocodazole in replating medium could not release KRIBB3-induced mitotic arrest 
of cells. This result confirmed that KRIBB3 arrested cell cycle at the same phase as 
nocodazole did. In addition, I tested whether detachment of cells by KRIBB3 is 
responsible for cell cycle arrest. For this, cells were replated into cell culture dish or 
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Petri dish on which cells could not attach. Cells could maintain cell cycle 
progression even in the absence of adhesion (Fig. 17C). This result suggest that de-
adhesion by KRIBB3 is not involved in cell cycle arrest at mitotic phase. 
 
3.4. Time-dependent effect of KRIBB3 in spindle checkpoint-competent cells 
 
KRIBB3 arrested the cell cycle at the G2/M phase (Fig. 16). Mitotic 
progression is controlled by APC/C, a multi-subunit E3 ubiquitin ligase (Peters, 
2006). In order to recognize and interact with mitotic substrates, APC/C requires a 
specific factor p55CDC (mammalian homologue of CDC20). The most downstream 
event in checkpoint regulation is the inhibition of p55CDC. Therefore, I decided to 
test whether KRIBB3 exerts its activity through APC/C inhibition. APC/C inhibition 
is accomplished by recruiting checkpoint proteins, including Bub1, BubR1, Bub3, 
Mad1, and Mad2 to unattached kinetochores (Weaver and Cleveland, 2005). 
p55CDC forms a complex with inhibitory Mad2, BubR1, and Bub3. Therefore, I 
examined whether inhibitory complex of Mad2/p55CDC was formed by KRIBB3 or 
not. For this, p55CDC was immunoprecipitated with antibody specific to p55CDC 
and immunoblotted with antibody specific to Mad2 (Fig. 18A). Inhibitory 
association of p55CDC with Mad2 was induced and reached its maximum 12 h after 
KRIBB3 treatment. Then, this inhibitory complex was decreased 24 h after the 
KRIBB3 treatment and disappeared 48 h after the treatment. However, expression of 
Mad2 and p55CDC was not altered by the KRIBB3 treatment. These results 
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suggested that KRIBB3 caused cell cycle arrest at mitotic phase through the 
formation of inhibitory checkpoint complex of Mad2/p55CDC. Furthermore, this is 
consistent with the observation that a decrease of the inhibitory complex resulted in 
a slippage of the mitotic arrest 48 h after KRIBB3 treatment. 
Substrates that are targeted for degradation by APC/C include the master 
regulator of mitosis, Cyclin B1. Therefore, if KRIBB3 could induce formation of 
inhibitory complex (Mad2/p55CDC) to inhibit APC/C activity, it should block 
Cyclin B1 degradation. To confirm this possibility, I accumulated Cyclin B1 by 
using nocodazole treatment and then analyzed whether accumulated Cyclin B1 was 
degraded in the absence or presence of KRIBB3. As shown Fig. 18B, when cells 
were arrested at G2/M phase by nocodazole (time 0), Cyclin B1 was highly 
accumulated. However, accumulated Cyclin B1 was disappeared within 3 h when 
replated in the medium with DMSO control. In contrast, accumulated Cyclin B1 was 
significantly maintained for 9 h when replated in the medium with KRIBB3. This 
result confirmed that KRIBB3 inhibited Cyclin B1 degradation by blocking APC/C 
activity.  
 
3.5. Induction of apoptosis by KRIBB3 is coupled with Bax activation. 
 
Cell cycle arrest at G2/M phase was begun 3 h after KRIBB3 treatment and 
more than 97% of cells were G2/M phase after 6 h (Fig. 19). This temporal pattern is 
very similar to formation of inhibitory complex (p55CDC/Mad2) (Fig. 18A). 
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However, amount of inhibitory complex was decreased 24 h after KRIBB3 
treatment and hardly detectable after 48 h. In addition, population of hypoploid (sub-
G0/G1) and PARP degradation were detected 24 h after the KRIBB3 treatment (Fig. 
16). These results suggested that slippage of cell cycle after arrest at mitotic phase 
could be important for induction of apoptosis. Therefore, I collected synchronized 
mitotic cells and analyzed cellular response for apoptosis in the presence or absence 
of KRIBB3. As shown in Fig. 19A, PARP cleavage was detected only from 
KRIBB3-treated cells. Bax is a proapoptotic protein of Bcl-2 family. In normal 
condition, Bax is mainly located in the cytosol as an inactive monomer. Upon 
stimulation by death signal, Bax is activated, resulting in a conformation change that 
targets it to the outer membrane of the mitochondria. Cells were collected at the 
indicated time and lysates were prepared with Chaps lysis buffer. Then, Bax 
activation was monitored by an immunoprecipitation-coupled western blot analysis. 
Monoclonal antibody Bax 6A7 can specifically precipitate the active conformers of 
Bax (Hsu and Youle, 1998; Tao et al., 2005). Fig. 18B showed that activation of Bax 
was detected only from lysates prepared from cells treated with KRIBB3. In 
addition, temporal pattern of Bax activation is very similar to that of PARP cleavage. 
These results supported that KRIBB3 induced apoptosis through activation of Bax. 
 
3.6. KRIBB3 inhibits microtubule polymerization in vivo and in vitro. 
 
 63 
It has been very well documented that microtubule inhibitors, including 
nocodazole, arrest cells at the G2/M phase and induce apoptosis. In addition, 
microtubules play crucial roles in maintaining cell morphology and shape. 
Interestingly, when cells were treated with KRIBB3, cells become round, arrested 
cell cycle at G2/M phase and underwent apoptosis. In the light of these observations, 
I speculated that microtubule and/or its function could be a potential target of 
KRIBB3. Therefore, immunofluorescence confocal microscopy was used to 
examine the effect of KRIBB3 on the microtubule cytoskeleton. The normal 
distribution of microtubules in untreated HCT-116 cells is shown in Fig. 20A. 
Paclitaxel treatment resulted in maintenance of microtubule polymerization with an 
increase in the density of microtubules. In contrast, treatment with KRIBB3 resulted 
in inhibition of microtubule polymerization and the appearance of short microtubule 
fragments in the cytoplasm. Similarly, treatment with nocodazole resulted in a 
diffuse stain visible throughout the cytoplasm, similar to staining for KRIBB3-
induced microtubule changes. 
Because KRIBB3 disrupted the microtubule organization in vivo, I further 
tested whether KRIBB3 directly inhibits tubulin polymerization in vitro. As shown 
in Fig. 20B, purified tubulins were polymerized to steady state in the presence of 
GTP at 37℃ in a control sample. As expected, treatment with KRIBB3 inhibited 
tubulin polymerization compared with DMSO. However, KRIBB2, an inactive 
structural analogue compound, did not inhibit tubulin polymerization. This result 
supports a structurally specific activity of KRIBB3 in microtubule polymerization. 
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In the presence of paclitaxel or nocodazole as a positive or a negative control, 
tubulin polymerization was enhanced or inhibited, respectively. 
 
3.7. KRIBB3 inhibits growth of HCT-116 colon cancer cells in BALB/c nude 
mice. 
 
A HCT-116 tumor xenograft model of nude mice was used to investigate 
inhibitory activity of KRIBB3 on tumor growth. HCT-116 cells were implanted 
subcutaneously into the right flank of nude mice on day 0, and the compound was 
administered intraperitoneally daily from day 1 at a concentration of 50 or 100 
mg/kg for KRIBB3 or 2 mg/kg for doxorubicin per day. To determine the toxicity of 
the compound, the body weight of tumor-bearing animals was measured. On day 16 
the mice were sacrificed and the tumors were removed and weighed. Sixteen days 
after implantation, tumor volume had decreased by 49.5% (50 mg/kg) and 70.3% 
(100 mg/kg) in mice treated with KRIBB3 compared to control mice (Fig. 21). 
There was no change in body weight when KRIBB3 was used at 50 mg/kg. 
However, when KRIBB3 was used at 100 mg/kg, there was 10.3% loss of body 
weight. Similarly, when doxorubicin was used as a positive control at 2 mg/kg, a 
20% loss of body weight was observed. 
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4. Discussion 
 
An unexpected finding of this study is that KRIBB3 inhibits tumor cell 
growth. KRIBB3 was initially discovered from chemical screening to identify 
inhibitors of migration (but not proliferation) of MDA-MB-231 breast cancer cells. 
However, it inhibited proliferation of a variety of other malignancies at sub-µM 
concentration except MDA-MB-231 and HT-29 (Table 1). KRIBB3 inhibits tumor 
cell migration and invasion by blocking PKC-dependent phosphorylation of Hsp27 
through its direct binding to Hsp27. Several other studies point to the ability of 
Hsp27 to increase the metastatic potential of tumor cells in nude mice as well as 
enhancing their resistance to therapy (Blackburn et al., 1997; Katoh et al., 2000). 
Higher levels of Hsp27 expression are commonly detected in variety different 
cancers including breast (Love and King, 1994; Oesterreich et al., 1993), prostate 
(Cornford et al., 2000), gastric (Ehrenfried et al., 1995), and ovarian (Arts et al., 
1999; Langdon et al., 1995) cancer.  
Initially, I believed that KRIBB3 blocked cancer cell growth through 
inhibition of Hsp27. In order to test this possibility, I used Hsp27 siRNA to 
knockdown of Hsp27 expression and examined its effect on cell proliferation (Fig. 
15). Surprisingly, knockdown of Hsp27 did not inhibit proliferation of HCT-116 and 
DU-145 cells. Therefore, I concluded that the effect of KRIBB3 on proliferation and 
cell cycle progression was not through Hsp27, but rather through another as yet 
unidentified KRIBB3 target. 
 66 
In order to determine the molecular mechanism of KRIBB3-dependent 
growth inhibition, I analyzed cell cycle progression in a time-dependent manner. 
Seventy percent of cells were arrested at the G2/M phase 12 h after KRIBB3 
treatment (Fig. 16A). Cell cycle arrest at G2/M phase was further confirmed by 
detecting G2/M phase-specific protein, Cyclin B1 and phosphorylation of Histone H-
3 (Ser 10) (Fig. 16D). There are many possible KRIBB3 targets responsible for 
KRIBB3-dependent G2/M phase arrest. Accumulation of Cyclin B1 implied that its 
degradation pathway could be blocked by KRIBB3. Cyclin B1 is degraded by 
proteasome in a cell cycle dependent manner after APC/C dependent-ubiquitination. 
APC/C activity is strictly controlled by mitotic spindle checkpoint machinery.  
Therefore, I decided to test whether KRIBB3 activate mitotic spindle 
checkpoint. APC/C-dependent ubiquitination is dependent on CDC20 (p55CDC, 
mammalian homologue) to recognize substrate. This substrate recognition protein is 
associated with its inhibitory protein Mad2. Therefore, I examined the formation of 
the inhibitory complex p55CDC/Mad2 in a time-dependent manner after KRIBB3 
treatment (Fig. 18A). As expected, KRIBB3 treatment induced association of 
p55CDC with the inhibitory protein Mad2. This inhibitory complex may block 
APC/C-dependent Cyclin B1 degradation. 
 This leads to the question of how KRIBB3 induces the inhibitory complex 
of p55CDC/Mad2. Because microtubule poisons such as vinca alkaloids cause all 
kinetochores to become unattached, thereby generating a mitotic-checkpoint signal, 
I decided to test whether KRIBB3 could inhibit microtubule structure. I carried out 
indirect immunofluorescence microscopy to check microtubule cytoskeleton in vivo. 
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Cells treated with KRIBB3 showed short microtubule fragments in the cytoplasm 
(Fig. 20A). This structure is similar to microtubules in cells treated with nocodazole. 
Furthermore, in vitro, purified tubulin polymerization was inhibited in the presence 
of KRIBB3 or nocodazole and enhanced in the presence of paclitaxel (Fig. 20B). 
The inhibitory activity of KRIBB3 on tubulin polymerization is similar to that of 
nocodazole. However, KRIBB2, an inactive structural analogue of KRIBB3, did not 
show any inhibitory effect on tubulin polymerization (Fig. 20B). Consistent with 
this, KRIBB2 did not inhibit proliferation of HCT-116 cells (Fig. 13). These results 
support my conclusion that inhibition of tubulin polymerization by KRIBB3 caused 
mitotic phase arrest and growth inhibition. 
 Because p53 has been shown to be involved in apoptosis and more than 
50% of human cancers have mutated p53, it is important for drugs to be able to 
induce apoptosis in a p53-independent manner. Therefore, we tested whether 
KRIBB3 could inhibit the growth of p53 null cancer cell lines. Fortunately, KRIBB3 
was able to induce cell cycle arrest at the mitotic phase, and apoptosis of both HCT-
116 (p53+/+) and DU-145 (p53-/-) cells. This suggests that induction of apoptosis 
following slippage of the mitotic checkpoint may not depend on the p53-mediated 
tetraploid checkpoint. 
Among 12 cancer cell lines, only MDA-MB-231 and HT-29 are relatively 
resistant to KRIBB3-induced growth inhibition (Table 1). Currently, I do not know 
the reason why these cells are refractory to KRIBB3. Currently, I do not know why 
these cells are refractory to KRIBB3, Recently, Tao et al. reported that cells that can 
sustain a long-term (48 h) arrest in mitosis (e.g., HT-29 colorectal adenocarcinoma 
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cells) are less susceptible to taxol-mediated killing than cells that more rapidly adapt 
into G1 after less than 24 h of drug exposure (e.g., HCT-116 colorectal carcinoma 
cells) (Tao et al., 2005). Therefore, it is likely that difference(s) in checkpoint 
response determine the sensitivity to inhibitors of microtubule dynamics. 
Normal cells have a robust mitotic checkpoint in which one unattached 
kinetochore can generate a signal strong enough to inhibit all cellular APC/C 
activity and therefore block progress to anaphase. However, when checkpoint 
components are mutated or their expression is low, they cannot produce strong 
enough signal to arrest cell cycle. When HCT-116 cells were treated with 1 µM 
KRIBB3 for 48 h, 43% of the cells were in the sub-G1 phase, indicating apoptosis 
(Fig. 16). However, when Human Foreskin Fibroblast (HFF) cells (normal cell line) 
were treated with 1 µM KRRIBB3 for 48 h, only 10% of cells were sub-G1 phase 
(Fig. 22). This result supports the hypothesis that HCT-116 cells are more sensitive 
to KRIBB3 than HFF cells. In addition many cancer cells divide in vivo more 
frequently than normal cells, and therefore frequently pass through a stage of 
vulnerability to mitotic poisons. Therefore, cancer cells may be relatively sensitive 
to KRIBB3 compared with normal cells. 
Failure in cancer chemotherapy is often related to multidrug resistance 
(MDR). Many microtubule-interacting drugs, such as the taxanes and vinblastine, 
are well-known substrates of P-glycoprotein (MDR1). This means that tumor cells 
can easily acquire drug resistance by overexpressing the MDR1 pump. The 
development of new compounds that are effective against drug-resistant cells is 
therefore important for cancer therapy. These results show that KRIBB3 exhibits a 
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similar potency regardless of the P-glycoprotein status (HCT-15 vs. HCT-116), 
indicating that KRIBB3 is not a substrate of P-glycoprotein, thereby suggesting that 
KRIBB3 is superior to other antimitotic agents in this regard.  
This study reports the biological properties of the low-molecular-weight 
compound KRIBB3, which displays strong antimitotic activity against cancer cells. 
In vitro, KRIBB3 exerts significant antitumoral activity against a variety of 
malignancies (colon, prostate, breast, and lung). The mode of action of the KRIBB3 
as a tubulin inhibitor was shown by in vitro tubulin polymerization assay and 
indirect immunofluorescence microscopy. The KRIBB3 selectively arrested cell 
cycle progression at the mitotic phase by activating mitotic spindle checkpoint. 
When KRIBB3 was administered, tumor volume decreased by 49.5% (50 mg/kg) 
and 70.3% (100 mg/kg) compared to control mice. The unique structural and 
biological properties of KRIBB3 make it an attractive candidate for further 
development toward potential clinical applications. 
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Fig. 13. Activity of isoxazole compounds on the proliferation of HCT-116 tumor 
cells. HCT-116 cells were treated with different concentrations of compounds or 
with vehicle solvent (0.1% DMSO) and viability were determined by using WST-1 
at 48 h after treatment. The results were expressed relative value to the vehicle 
treated cells.  
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Fig. 14. Activity of isoxazole compounds, paclitaxel, vinblastin, and colchicines 
on the proliferation of HCT-116 or HCT15 tumor cells. HCT-116 or HCT-15 
cells were treated with different concentrations of compounds or with vehicle 
solvent (0.1% DMSO) and viability were determined by using WST-1 at 48 h after 
treatment. The results were expressed as relative value to the vehicle treated cells.  
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Fig. 15. Knockdown of Hsp27 protein does not affect proliferation and cell cycle 
distribution. A, HCT-116 cells were transfected with siRNA as described in 
Materials and Methods, and then lysates were prepared with RIPA buffer. The 
whole cell lysates (30 µg) were separated using 12.5% SDS-PAGE, and blotted with 
anti-Hsp27 antibody or anti-Actin antibody. B, Proliferation of transfected HCT-116 
cells was determined by using WST-1 48 h post-treatment. The results were 
expressed relative to the vehicle-treated cells. C, HCT-116 cells were transfected 
with control (Con) siRNA or Hsp27 siRNA for 48 h and harvested, fixed, and 
stained with propidium iodide. 20,000 stained cells were then subjected to 
FACScalibur analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 74 
A. 
KRIBB3 (1 µM)   Nocodazole (1 µM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 hr 
1 hr 
3 hr 
6 hr 
24 hr 
48 hr 
12 hr 
0 hr 
1 hr 
3 hr 
6 hr 
12 hr 
24 hr 
48 hr 
 75 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. 
 
 
 
 
 
 
 
 
 
 76 
 
 
 
 
D. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16. KRIBB3 induces cell cycle arrest at G2/M phase and causes apoptosis.  
A. HCT-116 cells were treated with 1 µM of KRIBB3 for 0, 1, 3, 6, 12, 24, and 48 h 
and harvested, fixed, and stained with propidium iodide. 20,000 stained cells were 
then subjected to FACScalibur analysis. B. Relative percentages of cells in the Sub-
G1 (<2N), G2/M, S, and G0/G1 stages. C. Relative percentages of hyperploid (>4N). 
Populations were derived from the flow cytometric analysis in A. D. HCT-116 cells 
were treated with 1 µM of KRIBB3 for different times as indicated, and lysates were 
prepared with RIPA buffer. 20 µg of lysate were resolved by SDS-PAGE and 
immunoblotted with anti-Cyclin B1, anti-phospho-histone H3 (Ser 10), anti-PARP, 
or anti-Actin antibody. 
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Fig. 17. KRIBB3 arrests cell cycle at the same mitotic phase as nocodazole does. 
A. HCT-116 cells were treated with 1 µM of nocodazole for 15 h in order to 
synchronizing at mitosis, as described in “Materials and Methods” The collected 
mitotic cells were replated at 100 mm culture dishes in medium containing 0.1% 
Me2SO (DMSO) or KRIBB3 (1 µM). At the indicated time points after nocodazole 
release, cells were harvested, fixed, and stained with propidium iodide. 20,000 
stained cells then were subjected to FACScalibur analysis. B. HCT-116 cells were 
treated with 1 µM of KRIBB3 for 15 h in order to synchronizing at mitosis. The 
collected cells were replated at 100 mm culture dishes in medium containing 
nocodazole (1 µM) for 12 h. Then, cells were harvested, fixed, and stained with 
propidium iodide. 20,000 stained cells then were subjected to FACScalibur analysis. 
C. HCT-116 cells were trypsinized and collected. Then cells were replated in 100 
mm cell culture dish or Petri dish. After 24 h, cells were harvested, fixed, and 
stained with propidium iodide. 20,000 stained cells were then subjected to 
FACScalibur analysis. 
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Fig. 18. KRIBB3 induces formation of inhibitory complex of Mad2/p55CDC for 
APC/C blocking degradation of Cyclin B1. A, HCT-116 cells were treated with 1 
µM of KRIBB3 and incubated for different times as indicated. 400 µg of lysate was 
immunoprecipitated (IP) with anti-p55CDC antibody and protein G-agarose beads, 
and precipitants were resolved by SDS-PAGE after washing three times and 
immunoblotted with anti-Mad2 antibody or anti-p55CDC antibody. The same whole 
cell lysates (WCL) were resolved by SDS-PAGE and immunoblotted with anti-
Mad2 antibody, anti-p55CDC antibody, or anti-actin antibody. B, In order to 
accumulate Cyclin B1, HCT-116 cells were treated with 1 µM of nocodazole for 15 
h. The mitotic cells were replated at 100 mm culture dishes in medium containing 
0.1% Me2SO (DMSO) or KRIBB3 (1 µM). At the indicated time points after 
nocodazole release, cell lysates were prepared with RIPA buffer. 20 µg of lysate was 
resolved by SDS-PAGE and immunoblotted with anti-Cyclin B1 antibody or anti-
actin antibody.  
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Fig. 19. KRIBB3 activates Bax and induces apoptosis of HCT-116 cells. A, 
HCT-116 cells were treated with 1 µM of nocodazole for 15 h. The mitotic cells 
were replated at 100 mm culture dishes in medium containing 0.1% Me2SO 
(DMSO) or KRIBB3 (1 µM). At the indicated time points after nocodazole release, 
cells lysates were prepared with RIPA buffer or with 1% Chaps lysis buffer for 
active Bax 6A7 detection. 30 µg of lysate was resolved by SDS-PAGE and 
immunoblotted with anti-PARP antibody or anti-Actin antibody. B, 500 µg of Chaps 
buffer lysate was immunoprecipitated (IP) with anti-Bax 6A7 monoclonal antibody 
and protein G-agarose beads, and precipitants were resolved by SDS-PAGE after 
washing three times with Chaps lysis buffer and immunoblotted with anti-Bax 
monoclonal antibody. 30 µg of lysate was resolved by SDS-PAGE and 
immunoblotted with anti-Bax antibody. 
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Fig. 20. Effect of KRIBB3 on the organization of microtubule cytoskeleton in 
vivo and in vitro. A, HCT-116 cells were incubated with 0.1% Me2SO, 1 µM of 
nocodazole, 1 µM of taxol, or 1 µM of KRIBB3 for 6 h. The cellular microtubule 
network was analyzed by Carl Zeiss confocal system using monoclonal anti-α-
Tubilin antibody, fluorescein Texas Red-conjugated goat anti-mouse antibody, and 
4,6-diamidino-2-phenylindole. Scale bar, 10 µm. B, This assay was done using 
purified tubulins in vitro. The tubulins were incubated at 37  in the presence of ℃
vehicle (Me2SO), 3 µM of Taxol, 3 µM of nocodazole, 3 µM of KRIBB2, or 3 µM 
of KRIBB3 and microtubule formation was measured by spectrophotometer. 
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Fig. 21. KRIBB3 inhibits growth of HCT-116 colon cancers in nude mice. A. 
For the evaluation of in vivo anti-tumor activity of KRIBB3, HCT-116 cells (0.3 ml 
of 3106 cells/ml) were implanted subcutaneously into the right flank of nude mice 
on day 0. Compound was dissolved 0.5% Tween 80 and was daily administered 
intraperitoneally for 16 days at a concentration 50 or 100 mg/kg for KRIBB3 or 2 
mg/kg for doxorubicin. The dosage was 0.2 ml per 20 g body weight. These results 
were obtained from one assay using 24 mice (6 mice for each compound). Tumor 
volumes were estimated by the formula length (mm)  width (mm)  height 
(mm)/2, and the results were expressed relative value to the vehicle-treated mice. B, 
Body weight was measured on each indicated day using a balance.  
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Fig. 22. Temporal analysis of cell cycle distribution of HFF cells. HFF cells were 
treated with 1 µM of KRIBB3 for 0, 1, 3, 6, 12, 24, and 48 h and harvested, fixed, 
and stained with propidium iodide. 20,000 stained cells were then subjected to 
FACScalibur analysis. 
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Fig. 23. Temporal analysis of cell cycle distribution of DU-145 cells. DU-145 
cells were treated with 1 µM of KRIBB3 for 0, 1, 3, 6, 12, 24, and 48 h and 
harvested, fixed, and stained with propidium iodide. 20,000 stained cells were then 
subjected to FACScalibur analysis. 
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Table 2. Inhibitory effect of KRIBB3 on the proliferation of human tumor cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells were treated with different concentrations of KRIBB3 or 
vehicle solvent (0.1% DMSO), and proliferation was 
determined using WST1 at 48 h after the treatment. This data 
is from one of two independent experiments with similar 
results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumor cell line p53 GI50 (µM) 
HCT-116 Wild- type  0.35 
HCT-15 Deficient 0.3   
SW620 Deficient 0.8 
HT-29 Deficient 23  
HCA-7 Deficient  0.38 
MDA-MB-231 Deficient 25 
NCI-H23 Wild- type  0.64 
A549 Wild- type 1.2 
DU-145 Deficient  0.28 
PC-3 Deficient  0.48 
SK-OV-3 Deficient 0.6 
HeLa Wild- type  0.75 
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Ⅳ. Abstract in Korean 
 
 암이 생명에 위협이 되는 가장 큰 원인은 암세포의 전이성에 
있으며, 암으로 인한 사망의 대부분은 암 전이로 설명된다. 따라서, 
암세포의 침윤과 전이에 필수적인 세포이동이 암 치료에 있어서 좋은 
치료 표적이 될 수 있다. 암세포이동을 억제하는 화합물을 찾기 위해서 
화합물은행으로부터 분양 받은 합성화합물을 대상으로 탐색한 결과 CAC-
1098 (aurintricarboxylic acid) 및 CBI-0997 (5-(2,4-dimethoxy-5-ethyphenyl)-4-(4-
Bromophenyl) isoxazole) 두 개의 화합물이 유방암 세포주인 MDA-MB-
231 의 암세포이동을 IC50값 5 및 50 nM 농도에서 각각 저해하였다. 특히, 
CBI-0997 의 브롬 위치를 메톡시로 치환한 KRIBB3 (5-(5-ethyl-2-hydroxy-4-
methoxyphenyl)-4-(4-methoxyphenyl) 화합물도 MDA-MB-231 세포에서 
세포이동과 세포침윤 억제 활성을 나타내었으며, KRIBB3 화합물은 CBI-
0997 보다 좋은 drug-like 구조이기 때문에 세포이동억제 메커니즘을 
규명하는 일에 이 화합물을 사용하였다. KRIBB3 화합물에 결합하는 
단백질을 동정하기 위해 바이오틴(biotin)을 결합한 KRIBB3 를 
합성하였으며, 친화성 크로마토그래피(affinity chromatography) 방법을 
이용해서 KRIBB3 의 타깃 단백질이 Hsp27 단백질이라는 것을 동정하였다. 
MDA-MB-231 세포주에 PKC 활성물질인 PMA 를 처리하였을 때 PKC 에 
의존적으로 Hsp27 을 인산화 시켰으며, 세포 이동 또한 유도하였다. 
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대조적으로, KRIBB3 를 처리한 세포주에서는 PMA 에 의한 Hsp27 의 
인산화와 세포이동을 저해 시켰다. 또한, Hsp27 을 과발현 시켰을 때 
KRIBB3 에 의한 세포침윤의 억제효과가 상쇄되는 것을 알 수 있었고, 
siRNA 로 Hsp27 의 발현 양을 감소시켰을 때 세포이동을 감소시키는 것을 
알 수 있었다. 이 모든 결과를 종합해 볼 때 KRIBB3 가 직접적으로 
Hsp27 단백질과의 결합을 통해서 PKC 에 의한 Hsp27 단백질의 인산화를 
저해하고 그에 따라 암 세포의 이동과 침윤을 억제한다는 것을 보여주고 
있다.  
 KRIBB3 의 여러 항암활성을 관찰하는 동안 KRIBB3 가 여러 
암세포에서 세포 성장을 억제 시킨다는 것을 관찰하였다. 특히, 인간 
결장암 세포주인 HCT-116 에서 GI50 값이 0.35 µM 농도에서 세포 성장을 
억제하였다. Flow cytometry 연구에서 KRIBB3 가 세포주기중 G2/M 기에서 
세포주기를 정지시키고 세포사멸을 유도한다는 것을 관찰 하였고, 이 
사실은 Cyclin B1 의 축적과 세포사멸 마커인 poly (ADP-ribose) polymerase 
(PARP) 절편(cleavage)의 형태를 western blot 으로 증명하였다. 면역침강 
법으로 관찰한 결과, KRIBB3 를 처리한 초기에 APC/C 의 활성인자인 
p55CDC 와 억제단백질인 매드 2(Mad2)와의 결합이 유도된다는 것을 
확인하였으며, 이는 KRIBB3 에 의해서 유사분열 검사점(mitotic 
checkpoint)이 활성화 되었다는 것을 보여주고 있다. 그러나, 매드 2 와 
p55CDC 의 억제결합은 KRIBB3 처리 후 24 시간 때에 점차 감소하기 
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시작해 48 시간 때에는 관찰되지 않았으며, 이는 유사분열 검사점에서 
세포가 빠져 나왔다는 것을 의미한다. 이러한 실험결과들을 볼 때 
KRIBB3 가 미세소관(microtubule)을 망가뜨려서 유사분열 검사점을 
활성화 시켰다는 것을 보여준다. 이에 따라, 인 비트로(in vitro)와 인 
비보(in vivo) 실험인 튜뷸린 중합반응(tubulin polymerization)과 면역형광 
염색 실험을 통해서 관찰한 결과 KRIBB3 가 튜뷸린 억제제라는 것을 
증명하였다. KRIBB3 에 의한 일시적인 백스(Bax)의 활성은 PARP 절편과 
유사하게 관찰되었는데 이는 KRIBB3 에 의한 세포사멸이 백스를 통해서 
일어난다는 것을 보여주었다. KRIBB3 50 mg/kg 또는 100 mg/kg 를 
누드마우스의 복강에 투여했을 때, 49.5% 또는 70.3%의 종양성장 
억제활성을 나타내었다. 따라서, KRIBB3 가 항암치료에 좋은 항암제 
후보물질이라는 것을 보여주고 있다. 
 
